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The alveolar epithelial surface has been shown to be important in many forms of lung
injury (e.g. ARDS, pneumonia and fibrosis). Markers of cell specific injury to the lung
that can be measured in bronchioalveolar lavage would be advantageous as they might
allow study of damage to the alveoli in a non-invasive mariner. In this thesis a strategy is
described, using a bacterial model of pneumonia, for identifying markers specific for
individual cell types within the alveoli. Also, two putative cell specific antibodies
(MMC4 and MMC6) are further characterised to establish their potential as markers of
alveoli injury.
A rat model of pneumonia, caused by instillation of Staphylococcus aureus, has shown a
decrease in alveolar epithelial type I cells (AETI cells) and an increase in alveolar
epithelial type II cells (AETII cells) seventy two hours post-infection.
Injured regions from seventy two hour post Staphylococcus aureus infected lungs were
analysed via global gene analysis using Affymetrix® U34 gene chips. Overall 67 genes
were found to increase greater than 2 fold (F>0.05, P<0.001); of which 49 encode from
known proteins. 197 genes decreased 2 fold of greater (F>0.05, P<0.001) of which 125
translate to known proteins.
Searching the genes that decreased identified some proteins associated with AETI cells
(e.g. caveolin: 7 fold decease, P=0.017 and aquaporin 5: 2 fold decrease, P =0.01). This
suggests that this group of down regulated genes could potentially contain novel markers
that could identify reduced numbers of AETI cells. Within this group CD9 was found to
decrease. This was unexpected due to the influx of macrophages (known to be CD9
positive) into the site of injury. However, a literature search showed that CD9 is known
to be expressed in the alveoli, but is not thought to be cell specific.
Immunohistochemistry of frozen lung sections showed that anti-CD9 antibodies co-
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localised with AETI markers (caveolin, MMC6) but not AETII markers (RTII70,
MMC4).
MMC4 monoclonal antibody (IgG2a) has been proposed as an AETII and Clara cell
marker that recognises a protein novel to these two cell types within the lung, but the
antigen has not been characterised.
MMC4 antigen was immunoprecipitated from detergent-solubilized fractions of organ
homogenates using antibody-bound magnetic beads. The resulting purified protein was
trypsin digested and analysed via MALDI-TOF and tandem mass spectrometry. The top
'hit' in SWISSPROT for the antigen was aminopeptidase N (APN). The MMC4
monoclonal antibody was found to recognise a commercially purified APN. Further
analysis showed that the MMC4 monoclonal antibody was not a functional inhibitor of
APN and that the antibody was not binding to a glycans attached to APN.
MMC6 monoclonal antibody (IgG2b) was created at the same time as the MMC4
antibody. Initial studies showed that MMC6 recognises AETI cells within the lung. This
study shows that the antibody is recognising an antigen that is specific for the lung and
is only located on AETI cells within the lung. The antigen has been found to be an
integral membrane protein. Attempts at solubilizing the MMC6 antigen from the cell
membranes were not successful; however mechanical disruption did partially remove the
antigen from the cell membranes. Magnetic bead immuno-precipitation eluted a protein
of 60kDa. Unfortunately, due to low yields of the protein, identification was not possible
by MALDI-TOF or Edman degradation.
This thesis proposes a new way of interpreting global gene data to find proteins specific
to different cell types. We cast doubts on the specificity of some previously proposed
"specific" markers. It also highlights the pitfalls of claiming an antibody is a useful
marker of injury until the candidate biomarker has been fully investigated. The
continued emergence of CD proteins on alveolar epithelial cells within this study
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suggest that the alveolar epithelium may have more influence over the immune response
within the lung than previously realised.
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2. Introduction
Traditional drug development is expensive and time consuming; in 1992 the United
States Food and Drug Administration (FDA) added previsions for accelerated approval
of drugs based on data from biomarkers to be used in diseases with high mortality or
morbidity (Food and Drug Administration, 1992). Since this ruling, the majority of
cancer drugs that have been approved by the FDA have relied upon biomarkers to
validate them (Pien, 2005). Biomarkers, however, do present a new set of problems in
research as they can cause both false positive and false negative results due to poor
understanding of what the biomarker is measuring, or poor understanding of the
pathways that the disease follows. Better understanding of biomarkers during their
development and more rigid testing of them is therefore needed prior to their use. My
thesis looks at one method of identifying biomarkers (via genomics), highlighting areas
where problems arise with this method. I also carried out further analysis on two
potential biomarkers to asses their usefulness in classifying alveolar epithelial damage.
2.1 Architecture of the lung
The lungs are a highly specialised organ, which is adapted to facilitate gas exchange
between the blood and air. There are approximately forty different cell types within the
lung which are organised in a highly structured formation (Williams, 2003). The lungs
consist of a highly branching network of airways, which are made of rings of cartilage.
Inside the cartilage there is an inner membrane, which is covered with various epithelial
cell types. As the airways branch further they are no longer surrounded by cartilage and
eventually they split into the alveoli, where gas exchange with the blood occurs. Alveoli
are surrounded by a network of fine blood capillaries which covers approximately
126m~ (Schneeberger, 1991). Initially, it was thought that the air came into direct
contact with the capillary network of endothelial cells, or that there was thin mucus
forming the alveoli (Macklin, 1954). The presence of pulmonary epithelial cells
forming a continuous lining to the alveoli was first described in 1952 by F.N. Low as
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'Parent epithelial cells, located in the thicker, cellular portions of the alveolar wall
attenuate to an average thickness of 0.1-0.2p, forming a complete lining, and covering
the alveolar walls, facing on the air spaces.' (Low, 1952); although the findings of this
paper were not completely accepted at the time. The 'parent epithelial cells' he
described are now called alveolar epithelial type II cells (AETII) and the 'attenuated
cells' are the alveolar epithelial type 1 cells (AETI), both of which sit on the basement
membrane of the capillaries' endothelial cells (Figure 1). Different cell populations are
found in different areas of the lung and these perform specific functions. Below, I have
described some of the cell types of the lung with emphasis on where in the lungs they
are found and the cells' specialised roles within the lung.
2.2. Cell types found within the lung
2.2.1. Airway smooth muscle cells, alveolar myofibroblasts and pericytes
Airway smooth muscle cells, alveolar myofibroblasts and pericytes are all forms of
contractile cells that are found associated with the blood capillaries surrounding the
trachea, the bronchial passages and alveoli. Airway smooth muscle cells are found
surrounding the trachea and the bronchia passages (Janssen, 1997) all the way down to
the terminal bronchioles where they form an alveoli ring muscle (Kapanci, 1997).
Smooth muscle cells are also found around the division of blood vessels into capillaries,
where they are thought to be involved with regulating blood flow to the alveoli
(Kapanci, 1997). Pericytes are mainly found around the post capillary venules while
alveolar myofibroblasts are mainly found at the junction of three alveolar septa between
the endothelial and epithelial cell layers. As with smooth muscle cells these cells are
thought to be associated with regulation of blood flow through the capillaries (Kapanci,
1997).




Figure 1: Cartoon representation of the alveoli of the lung showing AETI cells
overlying the blood capillaries with AETII cells at the 'corners' of the alveoli.
Endothelial cells have been omitted for clarity of picture. Cells are not drawn to scale.
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2.2.2. Airway epithelial cells
Epithelial cells, be they in the airway (trachea and bronchi) or alveoli, share one
common role with all other epithelial cells of the body: they act as a barrier between the
body and the outside environment. 'Airway epithelial cells' is a generalised term that
covers a wide group of different cell types that are specialised to carry out other roles as
well as acting as a continuous barrier in the epithelium. These include ciliated cells,
taller cells, basal cells, goblet cells and Clara cells (Robbins, 1997). Ciliated cells make
up approximately half of the airway epithelial population, where their function is to
remove mucus secreted from the lung, taking with it any particles (dust, bacteria etc)
from the inhaled breath (Robbins, 1997). Clara cells will be discussed in greater detail
later.
2.2.3. Neuroendocrine cells
Neuroendocrine cells can be divided into two sub-populations: neuroendocrine epithelial
cells (located on the luminal surface of the trachea and bronchial tract) and
neuroendocrine cells (found in the pulmonary interstitial connective tissue).
Neuroendocrine epithelial cells are found scattered throughout the epithelial lining of the
aii-ways and also in clusters with Clara cells in the intrapulmonary airways. The main
function of these cells appears to be to decarboxylate amine precursor molecules.
Neuroendocrine cells in the pulmonary interstitium are not located within the epithelial
monolayer. Instead they are usually found in clusters with paraganglionic cells. These
clusters are often found near the blood capillaries and bundles of smooth muscle fibres.
Pulmonary interstitial neuroendocrine cells are also thought to be involved with the
decarboxylation of amide precursors (Scheuermann, 1997).
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2.2.4. Endothelial cells
Endothelial cells form the walls of the blood capillaries. In the lung they form part of the
blood-air barrier along with the alveolar epithelial cells. Endothelial cells form a
polarised monolayer of cells with cells joined by tight junctions to maintain cell polarity
and prevent molecular diffusion. Endothelial cells are large attenuated cells which, in
addition to their structural role, also are involved in the maintenance of the healthy lung
(Simionescu, 1997). Many inflammatory mediators (e.g. interleukins 1-16, tumor
necrosis factor and lymphotoxin) have an effect of endothelial cells. Tumor necrosis
factor-a, for example causes activation of phospholipases (in vivo), alteration in
thrombotic properties (in vitro), prostaglandin production (in vitro), increased cell
permeability, leukocyte adhesion molecule expression and chemokine production
(Silverman, 1997). The last three of these changes aid neutrophil and other leukocytes to
pass from the blood capillaries into the lung air spaces in situations of infection within
the lung.
2.2.5. Clara cells
Clara cells are non-cilliated cells found in the epithelial lining of the bronchioles
interspaced between the other airway epithelial cell types. Most in vitro work has been
carried out on Clara cells from the distal airways as these cells are found in greater
number in this area; however, the similarity of these cells to the Clara cells found
throughout the rest of the airways has been brought into question. (Plopper, 1997). The
main function of Clara cells is thought to be to the removal of particles from the lungs.
Clara cells share many of their functions with AETII cells (discussed later), such as
producing the major components of pulmonary surfactant (i.e. lipids and surfactant
proteins) and acting as progenitor cells (for ciliated cells). Clara cells also produce many
proteins involved xenobiotic metabolism (i.e. P450s, Clara cell secretary protein,
epoxide hydrolase and glutathione S-transferase) (Plopper, 1997).
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2,2.6. Alveolar epithelial type I cells (AETI)
AETI cells are large, attenuated, flat cells which form the main gas exchange surface of
the lung (Figure 1). In the rat, an average cell is 0.2pm thick, but has a surface area of
4500pm2 (Schneeberger, 1991), which aids gas exchange as the gases only have a small
depth of lung to diffuse through. The large surface area of AETI cells means that one
cell may line more than one alveolus (Williams, 2003). AETI cells are polarised, with
different proteins being expressed on the apical and basal membranes, aiding cells
functions. There are few organelles in type I cells, which originally led scientists to
believe that the type I cell was not involved in influencing the lung environment
(Schneeberger, 1991). However work as early as 1980 was showing that AETI cells can
influence the alveoli lining due to the presence of pinocytotic vesicles within the cells
which export products from the cells (DeFouw, 1980). It has also been shown that type I
cells have fluid transport proteins on the apical membrane e.g. AQP5 (see 2.2.6.1).
In the adult lung it is assumed that AETI cells do not undergo mitosis (Williams, 2003),
however this is hard to prove as type I cells have an average turn over time of 40-120
days, making analysis difficult. Foetal type I cells have been shown to be able to
differentiate back to type II cells (which is not thought to occur in the adult lung) and
these cells are then able to undergo mitosis to form either type I or type II alveolar
epithelial cells (Qiao, 2003). In the adult the main progenitor of type I cells are the type
II cells, however bone marrow stem cells (Kotton, 2001) have also been shown to be
able to differentiate into type I cells in vivo.
Investigations into type I cell functions and properties have been hindered by the
inability to isolate viable type I cells. The technique for isolation of AETI cells was first
described inl986 (Welle,r 1986), however, few research groups have been able to isolate
these cells with consistent results (Gonzalez, 2005). The majority of knowledge of type
1 cells has therefore come from work on either cell lines that are known to have type I
cell markers on their surface (e.g. SV40 cells, a cancer cell line), or on type II cells that
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have been allowed to differentiate in culture to a cell with type I cell morphology
(hereafter referred to as a type I cell-like cells), which also expresses type I cell associate
proteins. Both the cell lines and type I cell-like cells produce similar sugar binding
response to fresh type I cells as shown by their ability to bind lectins. Lectin binding was
used as an early method of differentiating type I and type II cells. Ricinus communis 1
lectin binds to AETI cells but not AETII cells while Maclura pomifera binds to AETII
cells, but not AETI cells (Brandt, 1982). This was one of the earliest indicators that type
I cells were functionally different to type II cells and not just stretched out type II cells.
Type I cells have since been shown to express proteins specific to type I cells, as well as
proteins that are not expressed by type II cells but are found elsewhere in the lung (see
table 1 for an overview ofAETI cell proteins). Recently Gonzales et al (2005) have also
shown that type I cell-like cells also express different proteins to both type I and type II
cells, which brings into question the use of type I cell-like cells and cell lines in the
investigation of type I cell functions. I have therefore split my description of type I cell
functions into two groups: those where the findings were found in primary culture (not
many) or were confirmed with in vivo results, and those where the findings have only
been found in vitro on cell lines/type I cell-like cells and are therefore possible roles of
the AETI cell.
2.2.6.1. Water transport
Water transport is important within the lungs to remove fluid just after birth, in
prevention of illnesses, such as asthma and pulmonary edema (Crandall, 2000) and in
resolution of illnesses by removing excess fluid released by necrotic cells. The level of
water within the lungs has to be maintained carefully as too little water causes the cell
surface of the alveoli to become dry and therefore gas exchange is reduced. If there is
too much water then the alveoli become full of liquid and therefore the air can not come
into close enough contact with the alveolar epithelial cells for gas exchange to take
place.
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Protein Location in AETI cell Expression in other cell types Ref
RTI40/TIa protein Apical plasma membrane None Dobbs,1988;Kato,
2003; Rasper, 1996
hti56 Apical plasma membrane None Dobbs, 1999
Caveolin-1/2 Microvesicles Endothelial cells, fibroblasts,






Basolateral membrane Ridge, 2003
Aquaporin 5 Apical plasma membrane Bronchial epithelial cells Nielson, 1997
Cytochrome P450
2B1
Cytoplasm Bronchial epithelial cells Takahashi,1994
Carboxypeptidase
M
Apical plasma membrane Alveolar macrophages Nagae, 1993
ICAM-1 Apical plasma membrane Alveolar macrophages, bronchial





Connexin 43 Cell membrane, cytoplasm ATII cells Abraham, 2001
p-glycoprotien Apical plasma membrane Smooth muscle cells, bronchial
epithelium, ATII cells?
Campbell, 2003
RAGE Basal membrane Some endothelial cells of larger





PAI-1 Apical plasma membrane ATII cells? Qiao, 2003
P2X4 purinoceptor Plasma membrane ATII cells? Qiao, 2003
CDKN2B Perinuclear ATII cells? Qiao, 2003










GGT Apical plasma membrane Clara cells, ATII cells Ingbar, 1995; Joyce-
Brady, 1994
















Table 1: Proteins known to be associated with AETI cells in normal adult lung
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Water movement is thought to be primarily through aquaporins (AQP) which are water
permeable integral membrane proteins that are unevenly distributed on cell membranes
throughout the cells of the lungs (Verkman, 2000). Alveolar epithelial type I cells are
known to have AQP 4 and AQP 5 on the apical surface (via immunohistochemical
studies) (Yasui, 1997, Verkman, 2000, Williams, 2003), but as yet no AQP has been
found on the basolateral surface of type I cells (King, 2001). AQP 4 is thought to be the
main aquaporins involved in removal ofpost natal fluid, due to experiments on knockout
mice (West, 2000). Aquaporin 5 knockout mice show no change in fluid clearance,
suggesting that AQP4 (or as yet un-identified aquaporins) can compensate for lack of
AQP5 throughout all stages of life (Williams, 2003).
There are currently four theories as to why aquaporins are not found on the basolateral
surface of type I cells:
1) They are there in small levels, but current methods for confirming their present
(immunohistochemistry mainly) are not sensitive enough.
2) There is an aquaporin present, but it is one that is yet to be discovered.
3) Fluid is removed from the type I cells in an aquaporin independent manner.
4) Type I cells do not transport the water, but use it to maintain their shape (i.e. it stays
within the cell).
Until recently, there had been no aquaporins found on AETII cells. However, Kreda et
al recently found that AQP 3 is expressed on the basolateral membrane of AETII cells
via immunohistochemistry (Kreda, 2001).
Aquaporins work by allowing water to move down an osmotic gradient (Kreda, 2001).
Within the alveoli the osmotic gradient is made by ion pumps, ion channels and ion co-
transporters. Just as AQP are unevenly distributed on cell surfaces, so are ion pumps,
channels and co-transporters (Matthay, 1996). Most of the work on ion movement has
been done on type II cells due to the difficulties in isolating type I cells.
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Alveolar epithelial type II cells actively pump sodium from within the cell out of the
basolateral membrane via Na, K-ATPase (an ion pump). However, sodium passively
enters the cell via amiloride-sensitive channels on the apical surface. Sodium transport
has also been shown to be important for the functioning of the type II cell as it is used in
co-transporters to facilitate glucose, amino acid, protons and phosphate entry into the
cell (Traebert, 1999).
In the last few years, papers from two different laboratories have been published that
show that AETI cells also actively transport sodium, and therefore AETI cells must also
affect water levels within the lung. Johnson et al (2002) showed that sodium uptake into
AETI cells are sensitive to amiloride, suggesting a sodium channel is involved (in vitro
data), and then later proved the presence of the sodium channel via
immunohistochemistry. They also showed that Na, K-ATPase is present on AETI cells
in the same way (activity blocked with ouabain) (Johnson, 2002). Borok et al (2002)
have also shown that type I cells have Na, K-ATPase activity by showing that they
produce mRNA for the protein via real time-polymerase chain reaction and
immunohistochemistry showed that the protein is found on the surface of the cell.
2,2.7. Alveolar epithelial type II cells (AETII cells)
AETI1 cells are cuboidal cells found in the 'corners' of the alveoli (figure 1). The main
distinguishing feature of type II cells are the characteristic lamellar bodies, which are the
surfactant stores of the lung (Mason, 1991). AETII cell are, like AETI cells, polarised
■y
cells, however, they have a far smaller surface area of approximately 70pm . Unlike
AETI cells, AETII cells have microvilli on the apical surface and projections into the
basement membrane which increase the surface area (Schneeberger, 1997). AETII cells
were first isolated in the early 1970's (Kikkawa, 1974) so there is a large body of
information on proteins known to be expressed by AETII cells. Fehrenbach et al (2001),
has a comprehensive list of proteins found on type II cells, however table 2 is an
abbreviated list of those proteins that are relevant to my thesis. AETII cells have long
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Protein Function Location in AETII cell Expression in other cell
types
Surfactant protein A Surfactant Secreted/ Lamellar bodies Clara cells
Surfactant protein B Secreted/ Lamellar bodies
Surfactant protein C Secreted/ Lamellar bodies




B-adrenergic Surfactant secretion Cell membrane Clara cells
receptors
Annexin II Exocytosis
Receptor for SP-A Surfactant
recycling
Cell membrane Clara cells
Alkaline
phosphatase
Lysosomal enzyme Lamellar body
Aminopeptidase N Differentiation? Cell membrane Macrophages
Retinoic acid Inhibits Cell membrane
receptor differentiation
CD95 Apoptosis Cell membrane Most
Bax Intracellular Most
Bcl-2 Intracellular Most




Hg-sensitive channel Cell membrane
(CHIP28)
Plasmalogen Antioxidant Secreted
Connexin 43 Gap junction
protein
Cell membrane AETI
CD44 Adhesion Cell membrane
E-cadherin Cell membrane
Ep-Cam Cell membrane
Entactin Extracellular Basal membrane












Mn superoxide Antioxidants Secreted
dismutase (SOD)
Table 2: Abridged list ofAETII cell associated proteins from Fehrenbach (2001).
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been known to be able to influence the environment around them. The most well known
of these is surfactant production (discussed below) although AETII cells also influence
the pH of the hypophase, fluid levels within the alveoli (discussed in relation to AETI
cells), and the host defence of the lung.
2.2.7.1. Progenitor cell
As already described, unlike AETI cells, AETII cells can proliferate. AETII cells act as a
progenitor cell for both new AETII cells and also AETI cells. It is unclear if it is all
AETII cells that have the ability to proliferate, or if it is a specific sub-population.
Reddy et al (2004) have found that, after injury with high oxygen levels, that they can
isolate a sub-population ofAETII cells that have a higher level of E-cadherin expression
than other AETII cells. They predict that these cells are the sub-population of 'stem'
cells within the lung. Critics of this argument say that the reason why only some of the
AETII cells show this increase in proliferative proteins is due to the other AETII cells in
the lung having been damaged.
2.2.7.2. Pulmonary surfactants
The inside of the alveoli are coated with a fluid bilayer with an aqueous subphase nearer
the cells which is then covered with a film of pulmonary surfactant (Pison, 1996). The
aqueous layer aids in gas exchange. This is where newly secreted surfactant material is
stored while they undergo extra-cellular modification and is where components of the
surfactant interact with host immune cells (Pison, 1996).
Pulmonary surfactant is a lipid rich layer, which prevents damage to the cells both
within the alveoli (Sutherland, 2001) and in the small airways (Pison, 1996), regulates
the surface tension within the lungs (Sutherland, 2001) and prevents the alveoli from
collapsing (Pison, 1996). Surfactant is produced within the alveolar epithelial type II
cells, where it is also stored in specialised organelles, the lamellar bodies. AETII can be
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stimulated to secrete surfactant by many chemicals (such as (3-adrenergic compounds
(Saldias, 2001)) and by mechanical stretching of the cells, such as taking deep breaths or
hyperventilating (Rose, 1999).
The major component of pulmonary surfactant is disaturated phosphatidychloride
(DPPC) (Mason 1977, Saldias, 2001), which, along with other lipids, helps to maintain
the low surface tension within the lung. DPPC is produced by a variety of different
pathways and enzymes within AETII cells (Tonks, 2005) so it is always found in the
lamellar bodies at high concentrations. As well lipids within the lamellar bodies, there is
also a range of proteins, most notably surfactant proteins A, B and C. Type II alveolar
epithelial cells also secretes surfactant protein D, complement components, lysozyme,
plasminogen activator, basement membrane components, cytokines, growth factors, and
hydrogen ions (See water transport) (Fehrenbach, 2001).
2.2.1.2.1. Surfactant protein A
Surfactant protein-A is the most abundant of the surfactant proteins (Tino, 1998, Pison,
1996). The main role of surfactant protein-A was thought to be to increase the surfactant
uptake ofAETII cells and decrease release of lamellar body contents into the alveolar air
space (Pison, 1996). However surfactant protein-A double knockout mice do not show
any differences with respect to the levels of surfactant within the lung when compared to
the wild type (Tino, 1998).
Surfactant protein-A has also been shown to be involved in the innate immune system
(Pison, 1996) due to its similar structure to mannose binding protein and Clq (both
opsonins of the innate immune system) (Folkesson, 2002, Pison, 1996). Surfactant
protein-A is thought to be able to bind to macrophages through the same receptor as Clq
as macrophages co-incubated with Clq subsequently have reduced binding to surfactant
protein-A (Tino, 1998). Surfactant protein-A can also directly affect macrophage
function within the lung by promoting chemotaxis (the movement towards foreign
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particles within the lung) and the oxygen burst within the macrophage (Pison, 1996).
The surfactant protein-A knockout mouse has not been characterised with respect to the
susceptibility to infections.
2.2.7.2.2. Surfactant protein B and C
Surfactant proteins B and C are hydrophobic proteins that appear to be involved in
reducing the surface tension within the alveoli (Pison, 1996). Within the surfactant
surfactant protein-B and surfactant protein-C make up approximately 8% and 4% of the
protein content respectively. Surfactant protein-B is thought to be important for the
correct formation of lamellar bodies within type II cells and is involved in the correct
formation of tubular myelin with surfactant protein-A (Ikegami, 1998). Surfactant
protein-B deficiency causes lethal respiratory failure at birth so it must be essential
(Ikegami, 1998). The roles of surfactant protein-C have not been classified due to
difficulty in purifying the protein and its tendency to denature and aggregate quickly
(Ikegami, 1998, Saldias, 2001).
2.2.7.2.3. Surfactant protein D
Surfactant protein-D, unlike all the other surfactant proteins, is not stored within
lamellar bodies in type II alveolar epithelial cells (Folkesson, 2002). It is, however,
synthesized by AETII cells as well as Clara cells (Folkesson, 2002, Pison, 1996). Unlike
the other surfactant proteins it is not specific to the lung and is also found in the gastric
mucosa (Pison, 1996 ). It does not have a role in maintaining the surface tension of the
lung, but like surfactant protein-A it has a role in the innate immune system. Like
surfactant protein-A it is a collagenous glycoprotein and calcium dependent (Folkesson,
2002). It is also similar in structure to mannose binding protein and thought to act in a
similar way to it.
Page 26 of 205
2.2.7.3. Repair of the damaged epithelium
After injury to the epithelium via a variety of agents it has been shown that the alveoli
looses AET1 cells as shown by the 'denuded' basement membrane characteristically
seen by electron microscopy. Over time, this 'denuded' membrane is covered with
cuboidal epithelial cells, which have been shown to produce many of the proteins
associated with AETII cells. Therefore, these cells have long been believed to be AETII
cells. However, recent findings by Clegg et al suggest that not all of these cells are the
same (Clegg, 2005). Clegg et al showed that some of these cells co-express RTI40 (an
AETI cell marker) and MMC4 (a potential AETII cell marker) possibly indicating cells
that are trans-differentiating into AETI cells. Other suspected AETII cells are thought to
undergo apoptosis to 'make room' for the new elongated AETI cells enabling the lung to
return to 'normal'.
2.2.7.4. Host defence
AETII cells produce many components of the innate immune system, such as C3, C4
(Fehrenbach 2001) which aid bacterial clearance form the lung by facilitating
recognition of the bacteria by neutrophils and macrophages. As already mentioned,
AETII cells also produce surfactant proteins A and D which also act as opsonins within
the lung to aid partial and pathogen removal. AETII cells also produce proteins that aid
in the recruitment of neutrophils and macrophages into the lung. MHC class II has been
shown to be produced by AETII cells under a variety of different conditions (Sherman,
1992) suggesting that AETII cells could have a role in antigen presenting and therefore
in the recruitment of T-lymphocytes into the lung.
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2.3. Regulation of cell numbers within the lung
The proportion of the lung covered by AETI and AETII cells seem to differ slightly
depending on which species being studied and the technique used. An example of this is
Crapo et al (1982) who used electron microscopy to count the number and type of cells
over 50 fields to determine the number of type I and type II cells within different species
(rat and human). In the human they found that AETI cells covered 92.9% of the lung
surface and make up 8.3% of the total lung cells, and type II cells covered 7.1%,
equalling 15.9% of the total lung cells. However, in the rat they found that AETI cells
covered 96.2% (8.9% of lung cells) and AETII cells covered 3.8% (14.2% of lung cells)
(Crapo, 1980). General consensus over type I /type II cell numbers seem to suggest that
95% of the alveolar surface is type I cells and 5% are type II cells and that these cells are
found in equal numbers (Williams, 2003).
2.4. Lung epithelia in studies of lung injury
Changes in the alveolar epithelium are found as a result of a large range of lung injuries.
Best known examples are acute respiratory distress syndrome (ARDS), thought to cause
36,000 deaths per year in the US (Matthay, 2003), idiopathic pulmonary fibrosis, which
affects 7-10/100,000 of the population (Pardo, 2002) and pneumonia which causes
approximately 1,000,000 hospital admissions per year in the UK (Davidson's, 2002).
2.4.1. Acute respiratory distress syndrome (ARDS)/ acute lung injury
ARDS is characterised by acute respiratory distress, decreased lung compliance, diffuse
infiltrates evident on the chest radiograph and reduced response to oxygen therapy
(Matthay, 2005) ARDS can be caused by a wide range of direct and indirect methods
(table 3). The most common cause is sepsis from Gram negative bacteria (Canonico,
1997). Studies into ARDS have shown a high influx of fluid into the lung (Matthay,
2005) which suggests that the alveolar epithelium is damaged, as epithelial cells have a
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Direct mechanism Indirect mechanism
Aspiration Sepsis
Diffuse pulmonary infection Severe non-thoracic trauma
Near drowning Hypertransfusion for emergency resuscitation
Toxic inhalation Cardiopulmonary bypass (rare)
Lung contusion
Table 3: Major direct and indirect causes of ARDS in humans (Canonico, 1997)
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lower water permeability than the underlying endothelial cells. There is also a decreased
clearance of water from the alveolar air space as shown by the decrease in the salt ion
transport from the alveoli. Ion transport from the lung is via AETI cells, indicating that
AETI cells are damaged in ARDS. Surfactant production is also reduced in ARDS, as
surfactant is produced by AETII cells, this could also imply a decrease in Type II cells.
Electron microscopy studies from patents that have died from ARDS also show a
decrease in the levels in type I and type II cells, with areas of the lung showing denuded
basement membrane. This is not found in electron microscopy's of the normal lung.
Current methods for predicting ARDS outcome include presence of chronic liver
damage, non-pulmonary organ dysfunction and advanced age. Other factors currently
examined, such as blood oxygen levels compared to oxygen levels being ventilated and
the lung injury score have shown no clear correlation to outcome of injury. Degree of
alveolar epithelial damage has been shown to be linked to patent outcome (Ware, 2000),
however, these studies have not characterised which cells within the lung are being
affected; nor do they give an indication of the likelihood of the patent progressing to
pulmonary fibrosis. A better knowledge of which cells within the alveoli are damaged
within ARDS could help clinicians plan suitable treatments more efficiently.
2.4.2. Idiopathic pulmonary fibrosis
Normal fibrosis in the lung is characterised by an increase in mesenchymal cells and
connective tissue matrix in a localised area of the lung. There is also injury to the
epithelial surface of the alveoli, with the alveoli being covered in cuboidal epithelial
cells instead of AETI cells. In severe fibrosis there is also a loss of blood capillaries in
the fibrotic area (Wolff, 1997). Idiopathic pulmonary fibrosis (IPF, also called
cryptogenic fibrosing aveolitis) is an end stage disease that can be reached via many
pathways depending on the type of initial injury to the lung. IPF is characterized by
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epithelial injury, formation of fibroblasts, myofibroblasts and extra cellular matrix
accumulation (Pardo, 2002). Patients with IPF normally survive for 4-5 years from onset
of symptoms with the ability of the lungs to transfer oxygen getting progressively worse
over time (Wolff, 1997).
The most common hypothesis of the pathgogenesis of fibrotic lung disease is that there
is a lung injury, followed by inflammation, then fibroproliferation and eventually
fibrosis (Selman, 2003). This assumes that inflammation precedes the fibrosis and that it
is necessary for fibrosis to occur. In most types of fibrosis this appears to be true,
however IPF does not always require a sustained inflammation stage (Selman, 2003).
Although inflammation can cause IPF, the alveolar epithelium is now also recognised as
a factor in the progression from lung injury to IPF (Pardo, 2002). Alveolar cell proteins
plasminogen activator inhibitor 1 (AETI cells) and 2 have been shown to be increased in
IPF, which may aid in a procoagulant/ anti-fibrinolytic environment being established,
which in turn, promotes fibrosis. Alveolar epithelial cells also produce many proteins
involved in the migration, proliferation and phenotype change of fibroblasts as well as
influencing the extracellular matrix. Examples of these proteins are: platelet-derived
growth factor, transforming growth factor beta, tumor necrosis factor alpha, connective
tissue growth factor and endothelin-1 (Pardo, 2002).
The alveolar epithelial cells themselves also appear different in the IPF lung. IPF lungs
have been shown to have hyperplastic type II cells, reactive large and elongated
epithelial cells (presumably AETII cells transdifferentiating into AETI cells) and flat
AETI-like cells overlying the fibroblast foci (Selman, 2003). All three of these have
links to AETI and AETII cells. Greater understanding of AETII cell migration,
proliferation and transdifferentiation could give insight into how these three situations
occur.
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2.4.3 Pneumonia
Pneumonia causes approximately 1,000,000 hospital admissions per year in the UK
(Davidson's, 2002) and many more people are treated within the community.
Pneumonia can be caused by a wide grange of different bacterial and viral pathogens,
the main ones are listed in table 4. More recently, the occurrence of colonisation by
more than one pathogen has also increased (Gutierrez, 2005).
Pneumonia is characterised by a new and persistent cough, often with sputum
production, fever and altered breathing sound. The 'gold standard' for diagnosis of
pneumonia is a chest radiograph showing shadowing within the lungs (British Thoracic
Society, 2001). This shadowing is due to a build up of fluid within the lungs. In animal
models it has been show that distal fluid removal is not affected by pneumonia, therefore
this reduction of fluid clearance is likely to be at the alveoli level (Boyer, 2005). As
AETI and AETII cells are the main site of fluid removal within the alveoli this suggests
that the alveoli are affected in pneumonia. A Staphylococcus aureus model of
pneumonia found increased levels of a AETI cell marker (RTI40) within the
bronchioalveolar lavage fluid 24 hours after instillation (McElroy, 1999) suggesting that
it is the AETI cells that are affected in pneumonia.
2.4.3.1 Animal models of pneumonia
Pneumonia is induced within animals by a variety of methods. The main three methods
are: instillation of the bacteria suspended in a saline solution via a tube inserted down
the trachea from the mouth (e.g. McElroy, 1999), instillation of bacteria bound to agar
beads via a tube surgically inserted into the trachea (e.g. Boyer, 2005), and insertion of a
fine thread into the lungs (e.g. Zagorul'ko, 1990). Instillation via the mouth of bacteria
suspended in saline carries the risk of accidentally instilling into the stomach in
inexperienced hands; however it does avoid the use of surgery needed to instil directly
into the trachea. Using agar beads also adds the injury caused by large particles being
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Causes of pneumonia Reference Cause of pneumonia Reference
Psuedomonas aeruginosa Chastre, 2002 Haemophilus inluenzae Gutierrez, 2005
Acinetobacter spp Chastre, 2002 Moraxella catarralis Gutierrez, 2005
Staphylococcus aureus Chastre, 2002 Adenovirus Gutierrez, 2005
Streptococcus pneumoniae Chastre, 2002 Varicella-zoster vims Gutierrez, 2005
Mycoplasma pneumoniae Gutierrez, 2005 Chlamydophila
pneumoniae
Gutierrez, 2005
Legionella pneumophilia Gutierrez, 2005 Chlamydophila psittaci Gutierrez, 2005
Table 4: Common causes ofpneumonia in humans.
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added into the lung. Use of a fine thread (such as fishing line) does appear to cause
pneumonia, however as pneumonia is rarely caused by insertion of fine thread in
humans, this method is not as favourable as the previous two for making comparisons
between human and animal pneumonia.
2.4.3.2 S. aureus induced pneumonia
Within our research group there is a previously established model for inducing acute
pneumonia within SD rats via instilling S. aureus bacteria into the lung via a tube
inserted into the mouth and down the trachea. Previous studies of the injury induced by
this technique has shown that levels of an AETI marker (RTI40) within the BAL fluid
increase 3 fold at 24 hours post instillation (innoculum of 4xl09) (McElroy, 1999). This
suggests that either AETI cells are being lost from the basement membrane into the
alveolar air space, or that the RTI40 antigen (Tla) is selectively cleaved from the AETI
cells after S. aureus induced injury. Electron microscopy studies of the lungs 24 hours
pos instillation show a basement membrane denuded of AETI cells suggesting that the
increase in Tla protein in the BAL is due to AETI cells in the airspace.
Three days post instillation lung homogenates from the injured regions of the S. aureus
infected lungs showed greater than 18 fold decrease in RTI40 reactivity via western blot
analysis (Clegg, 2005), suggesting that the damage to AETI cells carries on past the first
24 hours despite the animals behaving normally.
Immunohistochemistry of lungs 3 days post instillation showed a possible increase in
AETII cells shown by the increase in a potential AETII cell markers (MMC4) binding to
the lung samples. Western blot analysis also showed an increase in MMC4 antigenicity
(Clegg, 2005). This would fit in with the current thinking of how the lung repairs (see
2.2.7.3). Theses cells are not thought to be fully functional AETII cells however as
Clegg et al showed that they were also expressing the Tla protein, which is not
expressed by AETII cells under normal conditions.
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2.5. Biomarkers
2.5.1. What the law says about their use
Prior to 1992 for a drug to be approved it was evaluated via randomized, well controlled,
double blind studies. This enabled evaluating bodies and the public to be sure that the
drug/device being tested was thoroughly and scientifically evaluated, ensuring safety.
However, reliance on true endpoints (such as mortality or morbidity) caused potential
life saving drugs to be stalled in development and clinical trials for long lengths of time,
increasing the cost for drug companies and preventing treatments from reaching the
consumer. In 1992 this changed when the FDA added previsions for accelerated drug
approvals, for treatments of life threatening diseases (Food and Drug Administration,
1992).
In 1997 these powers were extended under Federal Law to allow the FDA to 'grant
marketing approval for a new drug product on the basis of adequate and well-controlled
clinical trial establishing that the drug product has an effect on a surrogate endpoint that
is reasonably likely, based on epidemiological, therapeutic, pathophysiological or other
evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint
other than survival or irreversible morbidity'(US Congress, 1997). This regulation was
the first that allowed surrogate endpoints to be used across all areas of research as
indicator of the true endpoint, however the key words here are the surrogate has to be
reasonable likely, based on various evidence, to predict clinical benefit. If a disease is
well understood, with a definite pathway of injury to disease to outcome, it is reasonable
to say that a biomarker is a good surrogate endpoint, such as high CD4 cell counts in
patients with HIV/AIDS corresponds to a decreased survival rate (Baker, 2005). If,
however, as more often occurs, the disease pathway is poorly understood, or it is
suspected that there is more than one pathway that leads to the disease state, or from
disease state to death, then saying that a potential biomarker is a good surrogate
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endpoint can be hard. Often this causes surrogate endpoints to be validated along side
the drug it is validating.
Despite problems with validation of biomarkers, between 1990 and 2002, 53 out of 71
oncology drugs approved by the FDA gained approval on the basis of surrogate endpoint
data, the remaining 18 relied upon traditional survival data. The most common surrogate
end point is tumour size reduction (Pien, 2005). Tumour reduction is not a key
biomarker in all types of cancer however; in colorectal cancer the correlation coefficient
between tumour response and survival was found to be 38% (Pien, 2005), suggesting
that in this cancer, using tumour size as a surrogate endpoint would be a bad idea.
2.5.2. Type of biomarkers
A biomarker is 'any substance or its products, structure or process that can be measured
in the body and that can influence or predict the incidence of outcome or disease'
(Gundert-Remy, 2005). Biomarkers are split into different types by the FDA. Type 0
biomarkers mark the natural history of a disease and correlate longitudinally with known
clinical indices, such as symptoms over the full range of the disease states. Type I
biomarkers capture the effects of an intervention in accordance with the mechanism of
action of the drug, even though the mechanism might not be known to be associated with
clinical outcome. Type II biomarkers are considered to be surrogate endpoints because a
change in that marker predicts clinical benefit. (Frank, 2003). Type 0 and type I
biomarkers, while useful in understanding a disease are not accepted as surrogate
endpoints, and are therefore not acceptable for drug approval.
Biomarkers can be further split into either different modes of measuring change or into
stages of clinical usefulness. If classifying biomarkers by method of measuring change
then most biomarkers fit into one of four groups: imaging biomarkers, DNA biomarkers,
RNA biomarkers and protein biomarkers. However assuming all biomarkers are
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eventually intended for use in the clinical setting, than a better method for classification
would be by their functional use, i.e. diagnostic, prognostic and drug selection.
2.5.2.1. Imaging biomarkers
Imaging biomarkers are mainly used with regard to tumours or diseases that cause a
large change to the architecture of an organ. The oldest technique for imaging diseases
is X-ray, which is still in use, both as straight images and as 3D imaging via computed
tomography (CT scans). X-ray is mainly used for 'hard' tissues such as bone scans or
when an image is required quickly to asses an injury (Pien, 2005). Magnetic resonance
imaging (MRI) is a preferred technique for soft tissues as it gives higher definition, such
as in cardiology where MRI scanning is used to asses plaque vulnerability (Frank,
2003). MRI can also be used in areas of the body where X-ray is not recommended,
however repeatability and standardisation of MRI machines have been found to be
challenging in multi centre trials (Pien, 2005). Another widely used form of image
analysis is Positron emission tomography (PET). Depending on the radioactive isotope
18
used PET scans can give information about cellular metabolism ( F-
llurodeoxyglucose), cell proliferation (l8F-fluro-L-thymidine) or apoptosis ("mTc-
annexin) (Park, 2004). PET scans are also in use in hospitals to image the inflammatory
component of vulnerable plaques in the heart (Frank, 2003) and in cancer research to
measure resistance to chemotherapy and angiogenesis (Park, 2004).
2.5.2.2. DNA biomarkers
DNA biomarkers work on the basis that people have a pre-determined susceptibility to a
disease (such as cystic fibrosis), that their body has particular polymorphs of a gene that
means they are more/less susceptible to a drug/disease or that a sub-population of cells
have had a mutation in the genome to cause a disease (I.E. cancer). DNA biomarkers
usually fall into one of four categories: changes in gene hypermethylation (which can be
measured in sputum) (Park, 2004), variations in single nucleotide repeats, microsatellite
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instability (Frank, 2003) or gross chromosomal aberrations. In December 2004 however
a DNA microarray looking at different types of P450 genes a person has was approved
by the FDA as a method of working out the speed at which a person will break down
specific drugs (Baker, 2005).
2.5.2.3. RNA biomarkers
RNA biomarkers work by looking at the mRNA that is produced by an individual/group
of individuals after an assault, compared to those with no assault. The theory is that
mRNA will be produced to overcome the injury, or in the case of cancers mRNA will be
being produced that would not be found in either healthy individuals or in non-affected
areas of the same individual. By profiling mRNA that has been up/down regulated by an
assault it would be possible to either a) screen people of whose status is unknown and
assign them to a group (affected/ not affected), or b) work out the best drug/therapy
regime to treat the individual based of the pathway their disease is following. RNA
biomarkers caused a big stir when they initially came on the market, but inteipretation of
the results has caused many problems in laboratories around the country due to the large
number of genes that are found to change, and the inability to asses which of these are
due to outside factors. Generally, most laboratories have found that the mRNA that
changes the most are markers of either general poor health and not changing due to the
specific disease being studied (Ilyin, 2004).
2.5.2.4. Protein biomarkers
The main advantage of protein biomarkers is that they usually use fluids that are easy to
access from the body, such as urine (diabetes), blood, sputum or bronchi-alveolar lavage
fluid. Most of these biomarkers are found by large screening of all protein in the fluid
via 2D electrophoresis (where the proteins are first separated by charge on a pH gradient
and are then separated via weight by traditional electrophoresis). Comparison of
proteins found in control and test subjects then allows candidate proteins to be found for
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biomarkers. This technique does however only work if the diseased state has a large
affect on one or more proteins, as the 2D gels only pick up big differences in levels.
Once a candidate has been identified an assay for that particular protein is then devised.
Some examples of biomarkers found in this way are: troponin C-reactive protein and
lipoprotein-associated phospholipase A2 (both associated with risk of heart
disease/stroke (Baker, 2005)). More recently protein arrays have started to be used
instead of 2D gels (Gundert-Remy, 2005). Other areas looked at have been protein
location within cells, modification of proteins (glycans, truncated forms of the protein
etc) and protein-protein interactions; however many of these techniques are only
currently being used in animal models to better understand the diseases as they require
biopsies (Ilyin, 2004).
2.5.2.5. Exhaled biomarkers
Many laboratories looking into lung disease are using exhaled gases as a way of
measuring the extent of specific diseases. Examples of these are nitric oxide, carbon
monoxide and hydrogen peroxide. Nitric oxide is produced by many of the cells within
the lung including macrophages and is up regulated by inflammatory cytokines and
endotoxin (Kharitonov, 2001). In viral infections, asthma and IPF nitric oxide levels are
found to increase, while in cystic fibrosis and ARDS it is found to decrease. Levels of
exhaled nitric oxide, interestingly, remain the same as for normal lungs in COPD
(Kharitonov, 2001). Carbon monoxide and hydrogen peroxide also give distinct patterns
as to how the gases levels increase/decrease. Interesting as this data is, as many different
diseases cause increases and decreases and as the affect of smoking (past and present)
has a large affect on the results, I feel that the possibility of using exhaled gases as a
reliable method of quantifying lung injury is slim.
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2.5.3. Biomarker uses in each stage of drug development
Potentially biomarkers can be used throughout all stages of drug development. In cancer
research biomarkers such as human epidermal growth factor and receptor-tyrosine
kinases, VEGF, ras and many more have been found to be linked to clinical out come for
specific cancers (Park, 2004). These proteins could therefore be used as drug targets to
reduce the proteins effect on the system. Biomarkers can help in optimising a drug
during development, for example by checking the percentage of the drug administered
reaches the organ of interest via PET scans. In pre-clinical studies, where typically
animal models are used (with the well documented limitations of diseases not
performing the same as they would in humans), markers that can be found to correlate
with the human disease can greatly assist in authenticating the model (Lee, 2004), and
therefore the drug being trialled. Once a drug is in phase I/II trials appropriate
biomarkers can help with assessing correct dosing (such as the P450 chip for drug
metabolism), again PET scans are useful to check that the drug is finding the correct
target and mechanistic biomarkers could also help select people to by put on the trial
regime (I.E. when there are diseases with similar symptoms, but caused by different
mechanistic pathways). In Phase III trials the development of a surrogate end point, so
that accelerated or full drug approval and registration can occur, is a great benefit as it
saves the drug company from having to wait for traditional endpoints of the disease.
2.5.4. Markers in the clinical setting
Biological markers are used right through clinical medicine, from diagnostic markers to
prognosis markers to selection of patents to particular drug regiments. Diagnostic
markers are used to identify diseases at early onset before clinical symptoms are readily
visible, or when two different conditions have similar morphology (e.g. free PSA in the
sera differentiates between prostatic hyperplasia and cancer (Ludwig, 2005)). The
advantage of biological markers in this setting is it allows for quick identification of the
disease which therefore allows treatment to start earlier. Prognostic markers predict the
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likelihood of survival from a disease, or the likelihood of reoccurrence of a disease. In
December 2004, the FDA approved the first DNA microarray test for gauging speed of
drug metabolism, which is based on the number of SNP and haplotypes of Cytochrome
P450 (Frank, 2003, Baker, 2005). Markers like this allow physicians to select drug
regimes and dosages based on the likely reaction of a patient to the treatments.
2.5.5. Why biomarkers should be thoroughly investigated
Biomarkers, while proving useful in reducing the length of time required for drugs to go
forward to clinical trials, also can produce problems. If it is not thoroughly understood
what a biomarker is measuring (and how this relates to the disease) then any
decrease/increase in the levels of the marker can not be accurately interpreted. Most
biomarkers that do fail fall into one of four categories:-
1) Those that recognise one pathway of a disease but not all possible pathways
(false negative)
2) Marker recognises a molecule which is increased as an effect of the disease, but
the molecule is not part of the disease pathway.
3) Marker recognises more than one molecule which can cause false positive/
negative results.
4) Marker does not recognise an extra effect caused by the treatment.
Examples of trials that have used biological markers to assist in drug validation where
the results from the biomarker have given false positive or false negative results include
the Cardiac Arrhythmic Suppression Trail (CAST) (Baker, 2005), fluoride treatment for
postmenopausal osteoporosis and Rifaximin treatment of Diarrhea (Steffen, 2003). In
the Cardiac Arrhythmic Suppression Trail people who had a heart attack and
subsequently diagnosed with ventricular arrhythmia were given trial drugs which
reduced the arrhythmia. These drugs had been shown to work based on
electrocardiograms on a few hundred patients. The drugs reduce the arrhythmia within a
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few weeks, and based on this the drugs were put forward as a treatment that reduces the
mortality rate from this condition. However, after a year long study into these drugs, it
was found that patients that were being treated with the drugs had a 2.5 fold greater
chance of dying than the control group (Baker, 2005). In this case exactly why the drug
caused such a different result from that expected has not be reported in the literature,
however it is most likely that this trial failed because the proposed marker (regularity of
heart beats) is not a marker for all possible pathways that could result in a heart attack.
Fluoride treatment for postmenopausal osteoporosis showed that the treatment, which
increased bone density, but did not decrease the rate of fractures. This was found to be
due to the decrease in bone quality in these patients. This marker appears to have failed
as it did not recognise an alternative effect caused by the treatment (type 4 fail)(Baker,
2005).
Other studies, such as Rifaximin, produced a positive result with regards to symptoms
(the traditional method of measuring a drugs success), however the Biomarker being
used to test the effectiveness of the treatment (pathogen levels in stools) remained
constant (Steffen, 2005). This suggests that Rifaximin is affecting more than one
pathway within the body and 'masking' the symptoms of the pathogen while not
eradicating the pathogen. Studies like these highlight the importance of detailed
investigations into how biomarkers are linked to disease pathways and how diseases
progress to the clinical endpoint.
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3. Purpose ofmy study
As the alveolar epithelia is affected in many lung diseases and can affect the outcome of
the disease (resolution of fibrosis) a better understanding of how AETI and AETII cells
are affected and respond to injurious agents could help in producing drugs to aid normal
lung resolution. Biomarkers of the epithelial cells would allow researchers to follow the
progression of an injury via secreted biomarkers (in BAL fluid of sputum for example)
and by staining lung sections (from biopsy or tissue taken at death). Proteins, which
could be biomarkers, are already known for both AETI and AETII cells, however, only
one of the AETI cell proteins is specific for AETI cells within the lung (RTI40), and it
recognises a protein to which no know function has yet been assigned. As such this is
not very useful as a biomarker as, with no known function, explaining increased and
decreases in its levels after injury is difficult as it is unknown if the injury is causing the
affect to the protein specifically, or to the number of AETI cells. SP-A and SP-D have
been proposed as markers for AETII cells, however as these proteins are also expressed
by Clara cells the changes in levels in the BAL/sputum can not be assumed to AETII
cells meaning that a biopsy would be required to make this an effective biomarker.
In my research I therefore planned to see if I could identify potential markers of
AETI/AETII cells by looking at proteins that are not currently considered to be
expressed in the lung. I also planned to further investigate two potential biomarkers that
had been made in our laboratory group, to asses their usefulness as biomarkers of the
alveolar epithelium.
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4. Hypotheses
la) Global gene analysis of RNA from Staphylococcus aureus injured lungs can
further characterise the 72 hour rat model of pneumonia.
lb) An animal model of 72 hour Staphylococcus aureus injury to the lungs could be
used to identify new biomarkers of the alveolar epithelium using Affymetrix U34
gene chips.
2a) A potential biomarker in the literature (MMC4 monoclonal antibody) (Boylan,
2001) recognises a novel protein on AETII and Clara cells.
2b) MMC4 monoclonal antibody is a useful biomarker of AETII and Clara cell
injury in the rat.
3a) A potential biomarker of AETI cells (MMC6 monoclonal antibody) recognises a
protein novel to AETI cells.
3b) MMC6 monoclonal antibody is useful as a biomarker of AETI cell injury in the
rat.
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5. Materials and Methods
All reagents, unless otherwise stated, were supplied by Sigma
5.1 General techniques
5.1.1. Organ isolation and storage
All organs (except ovaries and placenta) were isolated from healthy, adult, male, specific
pathogen free (SPF) Sprague Dawley (SD) rats (Harlow UK) over 300g (n=32). Ovaries
and placenta were isolated from healthy, adult, female SD rats (ex-breading stock)
(n=4). Rats were euthanized via a lethal dose of anaesthetic (Sagital (60mg/Kg) or
Ketermine/Hypoval (133mg/Kg and 13.3 mg/Kg respectively) injected into the
intraperitoneal cavity.
Once animals had stopped breathing the abdomen and rib cage were opened. A
tracheoscopy was preformed and a shortened wide boor syringe was inserted into the
trachea. The lungs were lavaged twice with tris buffered saline (TBS) (containing NaCl
(0.154M), Trizma base (0.02M), pH8.2) or phosphate buffered saline (PBS) (with
Ca2+/Mg2+). The lavage was preformed by using a 10ml syringe to add 10ml of
TBS/PBS to the lungs via the tube inserted in the trachea. The saline solution plus lung
contents were then removed from the lungs via suction using the syringe. Lavage fluid
was stored on ice until needed. Lungs were then perfused with TBS or PBS. Perfusion
was carried out by attachment of an empty 10ml syringe to the trachea tube and insertion
of a 50ml syringe containing TBS/PBS into the right ventricle of the heart.
Simultaneously the lungs were inflated/deflated with the 10ml syringe and the TBS/PBS
was added to the heart. Once the lungs went white in appearance they were removed
from the rat by cutting down behind the trachea and lifting the lungs away. Lungs were
then stored on ice until needed.
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A section of the small intestine (just distal to the stomach, approx 10cm), the stomach
and a section of the large intestine (approx 10cm) were then removed. The contents of
all three were squeezed out gently before these organs were placed on ice. All other
organs were removed and stored on ice.
All organs were washed in TBS with Complete" protease inhibitor (Roche) added as per
the manufacturer's instructions. The tissues were homogenised in TBS with Complete®
protease inhibitor (ratio 1:5 weight to volume) at 13,000rpm using an Ultra Terrax T25
basic homogeniser (Werke) and then spun at 300g for 3 minutes to remove larger tissue
pieces. (Here after the supernatant is referred to as 'homogenate'.) Aliquots of the
homogenates were then stored at -70°C until needed.
5.1.2. Bradford protein assay
Bradford assay (BioRad) was used to measure protein concentrations of all samples
initially. Briefly, 40pl Bradford reagent was diluted with 150pl water and lOpl sample
was added. The absorbencies of the samples were measured using an ELISA plate reader
(MRX, Dynatech laboratories) at 600nm. Each sample was tested at two different
dilutions and with three repeats of each dilution. Samples were compared to a standard
curve of Bovine Serum Albumin (BSA) (Pierce) (0-1,2pg protein).
5.1.3. Lowry protein assay
A modified Lowry protein assay (Lowry, 1951) (BioRad) was used to measure the
protein concentration of samples containing detergents (due to detergents interfering
with the Bradford assay). Briefly, 20pl of samples were incubated with copper tartrate
and SDS (Sodium dodecyl sulphate) for 5-10 minutes, with shaking, at room
temperature in a 96 well plate (NUNC). Folin reagent was added and incubated at room
temperature, with shaking, for 15 minutes. The absorbencies of the samples were
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measured using an ELISA plate reader at 630nm. Each sample was tested at two
different dilutions, and with three repeats of each dilution. Samples were compared to a
standard curve of BSA also with detergent added at the same ratio of 1:5 mg protein
(determined by Bradford assay before the addition of detergent) to mg detergent.
5.1.4. Enzyme-linked immunosorbant assay (ELISA)-based dot blot
Immobilon-P transfer membrane (a polyvinylidene fluoride (PVDF) membrane)
(Millipore) was hydrated via a methanol wash followed by repeated washing in distilled
water. Samples, suspended in TBS, were vacuumed onto the hydrated PVDF membrane
using a dot blot manifold (figure 2) (Schliecher & Scheuell). The PVDF membrane was
then incubated in casein (2.5% w/v in TBS) for 1.5 hours to block the PVDF membrane,
preventing any other protein binding to the membrane. Half the blot was then incubated
with the primary antibody (see table 5 for a list of primary antibodies used) for 30
minutes, while the other half of the blot remained in blocking buffer. Both halves of the
membrane were washed with TBS-Tween (polyethtlene sorbitan monolaurate) (0.5%
v/v) for 30 minutes and then incubated with IgM anti-mouse-IgG-HRP (0.1% v/v, casein
(2.5% w/v) in TBS) (Rockland c/o Lome Laboratories) for a further 30 minutes. After
washing with TBS-Tween, again for 30 minutes, the membranes were added to
electrogenerated chemiluminescence detection reagents (GE Healthcare). Immediately
the membrane was exposed to Biomax Light X-ray film for various lengths of time
(typical exposure times were 15 seconds, 30 seconds, 1 minutes and 2 minutes). After
development in a X-ray development machine (Biorad), the film was attached to the
bottom of a 96 well plate and read in an ELISA reader at 630nm (MRX, Dynatech
laboratories). To allow for variations between blots, all samples to be compared and
controls were loaded onto one membrane.






Top layer of manifold,



















Figure 2: Assembly of the dot blot manifold for EL1SA based dot blots. Samples, mouse
serum or water was loaded into the wells the vacuumed onto the PVDF membrane.
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Antibody Isotype Raised
in
Dilution in DMEM and
10% foetal calf serum
Antigen Antibody
source
MMC4 IgG2b Mouse Hybridoma supernatant APN McElroy




MMC6 IgG2b Mouse Hybridoma supernatant Unknown McElroy
Table 5: Antibodies used for ELISA based dot blot analysis of sample.
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5.1.5. Sodium dodecyl sulphate -poly acrylamide gel electrophoresis (SDS-PAGE)
Six, eight or ten percent acrylamide separating gels (see table 6 for recipes) were poured
into BioRad equipment and allowed to set for 30 minutes. A stacking gel (table 6) was
then loaded on top of the separating gel into which a 10 or 15 well comb was placed.
Once the gel had set the apparatus was assembled and a running buffer (containing Tris
(25mM), glycine (192mM) and SDS (0.1% v/v) at pH 8.3) was added to both upper and
lower chambers. Samples and molecular weight markers (GE Healthcare), diluted in
sample buffer (without mercaptoethanol), were loaded into the wells. The gel was run at
100-130 volts at 4°C until the dye in the sample buffer ran to the bottom of the gel.
The gels were then stained with Gelcode (Pierce), Rapid silver stain (Gottlieb, 1987) or
Proteosilver Plus (Gharahdaghi, 1999, Rabillaid, 1994) as per manufacturer's guidelines.
Bands required for further analysis were excised from the gel and stored at -20°C. Gels
were then dried either via the heat/vacuum method (equipment from BioRad), or using a
TUT's Tomb air drier (Matsvdaira, 1978). Gels and membranes (Promega) for the
TUT's Tomb drier were pre-soaked in 5% glycine, 10% ethanol for 30 minutes before
apparatus was assembled.
5.1.6. Harvest of lungs for immunohistochemistry
Rats were euthanased via a lethal dose of pentobarbital and 0.7ml heparin via an IP
injection. Blood was then extracted from the aorta. A tracheotomy was performed and
2x10 millilitres sterile PBS with Mg2+/Ca2+ were used to lavaged the lungs. Lungs were
then perfused with 50 millilitres sterile PBS with Mg2+/Ca2+ before inflating the lungs
with paraformaldehyde (4% w/v in PBS without Mg2+/Ca2+). Lungs were removed from
the rat and suspended in paraformaldehyde for 24 hours at room temperature. Small
areas of the lung were then dissected out and stored at 4°C in 30% sucrose for a further
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Water 7.9 6.9 5.9 3.4
Acrylamide/Bis (30% T, 2.67% C) (37.5:1 mixture) 3.0 4.0 5.0 0.83
1,5M Tris-HCl, pH 8.8 3.8 3.8 3.8 0
l.OMTrisHCl, pH6.8 0 0 0 0.63
10% (w/v) SDS 0.15 0.15 0.15 0.05
10% (w/v) ammonium persulfate 0.15 0.15 0.15 0.05
TEMED 0.012 0.0009 0.0006 0.005
Table 6: Recipes for Tris-glycine SDS-Polyacrylamide gel electrophoresis resolving
gels.
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24 hours. The tissue was then rapidly frozen and cut into 5 micron sections. These
samples were then fixed to glass slides and stored at -20°C until needed.
(Freezing, cutting and fixing to slides was performed by S. Harvey).
5.1.7 Immunohistochemical staining of frozen lung sections
Frozen sections of lung prepared as above were washed in PBS with Mg2+/Ca2+ then
incubated in blocking buffer containing 0.1% Triton X-100 (0.352% fish gelatine, 20%
goat serum, 0.1% Triton X-100 in PBS with Mg2+/Ca2+) for 20 minutes. After washing
with PBS, slides were incubated with primary antibodies (see table 7 for antibodies and
quantities used) made up to lOOpl in blocking buffer for 20 minutes. Slides were
washed, again in PBS, and then incubated with the appropriate secondary antibodies
(Calbiochem) (in lOOpl blocking buffer) for 15 minutes (see table 7). If nuclear stain
was to be added then TP3 (Calbiochem) (diluted 1:100 in blocking buffer) was added
after a further wash and left for 10 minutes. After a further wash cover slips were
mounted using Dako mounting medium. Slides were scanned using wavelengths of
488nm (green), 546nm (red) and 647nm (blue) depending on the secondary antibody
used.
5.1.8. Statistical analysis
Values are shown as the mean average with conservative standard deviations. Where
significance has been shown first the data was F-tested to ensure that the values had a
similar distribution profile, followed by the Student t-test assuming two tailed
distribution and equal variance (as shown by the F-test). Statistics were carried out in
Microsoft Excel and GraphPad Instat.









MMC4 1:2 Anti-mouse IgG2a 1:100 McElroy
MMC6 1:2 Anti-mouse IgG2b 1:100 MeElroy
RTI40 1:100 Anti-mouse IgGl 1:100 Dobbs
CD9 1:50 Anti-mouse lgG3 1:100 BD Biosciences
CD68 1:50 Anti-mouse IgGl 1:100 Serotec
Table 7: Primary and secondary antibodies used for immunohistochemical analysis of
frozen lung sections. All secondary antibodies were from Calbiochem.
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5.2. Chronic Staphylococcus aureus model of pneumonia in rats
All bacterial work was carried out using sterile equipment and techniques in a Class II
safety hood.
5.2.1 S. aureus stock production
Single colony forming units (CFU) of S. aureus strains 8325-4 and 8325-4 PLs grown
on blood agar base plates (DB Biosciences) were added to 3ml Todd Hewitt broth
(Fisher Scientific) and incubated for 16 hours at 37°C in an orbital shaker at 300 rpm.
The resulting bacteria broth was added to 7ml glycerol, split into 500pl aliquots and
stored at -70°C. If a stock solution of broth completely thawed out, it was not re-frozen
as it was found that repeated freeze-thawing cycles killed the bacteria.
5.2.2 S. aureus culture
Scrapings (<10pl) of the glycerol frozen S. aureus were streaked out onto blood agar
base plates and incubated at 37°C for 16 hours to produce single colony forming units.
A single CFU from the plate was then transferred to 3ml Todd Hewitt broth in a 12ml
bacteria tube. Tubes were turned to be horizontal and shaken for 30 seconds to maximise
the aeration of the broth. Tubes were incubated for 16 hours in an orbital shaker at
300rpnr and 37°C.
5.2.3. Instillates
The optical density of the Todd Hewitt broth at 600nm was measured and was
compaired to a previously established standard curve to give a rough guide to the colony
forming units per millilitre (cfu/ml) of the broth. From this, it was calculated how much
broth would be needed to give 7-9x108 cfu/ml. After dilution in PBS with Mg2+/Ca2+,
1,5ml of broth was washed 3 times via centrifugation at 13000g for 3 minutes, the pellet
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was re-suspended between each wash in 1.5ml fresh PBS. The bacteria were finally re-
suspended in 1.5ml PBS. Ten microlitres of each instillate was removed, diluted and
plated on blood agar plates to confirm cfu/ml and also the antibiotic resistance of the
8325-4 PLs strain.
5.2.4. Instillation
SD SPF rats (300-350g) were stored in groups of 4 in closed bottom cages with free
access to food and water. Animals were stored in a separate room to prevent distress
due to excessive noise/movement. Sixteen hours before the start of the procedure the
required animals were removed to the procedure room to allow them to settle before
they were instilled. To prevent stressing the animals, all work was carried out in silence.
Rats were anaesthetised with a Hypnoval/Hypnorm mixture (0.2ml Hypnoval plus 0.2ml
Hypnorm plus 0.8ml water) via an IP injection. Once anaesthetised rats were weighed
and suspended over the apparatus shown in figure 3. A fine tube was passed down the
trachea and through this 0.5ml of instillate or 0.5ml PBS was passed, followed by 2ml of
air. Generally, this led to bacteria being instilled into the left lung lobe. The rats were
then placed back in their cages on paper to prevent inhalation of the wood shavings.
Cages were placed in a Class II safety hood on top of a heating pad. Rats breathing
status during and immediately after instillation were recorded. Further recordings of
animals breathing, motility, colour and weight were taken every 2 hours post instillation,
until 8 hours post instillation and then again at 24 and 48 hours post instillation. Twenty
four hours after instillation animals were returned to their usual holding room.
5.2.5. Harvest for protein analysis
Rats, at various time points after instillation, were given a lethal dose of pentobarbital
and 0.7ml heparin IP. Blood was then extracted from the aorta, and plated out on blood
agar plates to check for bacteria and in the case of 8325-4 PLs, antibiotic resistance. The
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Figure 3: Drawing of the stand used to drape rats over for instillation of bacteria. Rats'
front teeth were placed over top wire and front feet were placed on spring at bottom.
This ensured that the rats mouth remained open and that the trachea was straight. A fine
tube was then passed down the trachea via which bacteria suspended in PBS or PBS was
instilled into the lungs.
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remaining blood was spun at 2500rpm for 20 minutes and the serum was collected and
stored at -70°C. The diaphragm was then perforated and 2ml PBS with Mg2+/Ca2+ was
used to wash the plural cavity. Plural fluid was plated on blood agar based plates to
check for S. aureus and the level and type of white blood cells were analysed as
described below. Leukocytes were then removed from the plural fluid prior to its storage
at-70°C.
A tracheotomy was then performed. The rib cage was cut open so that the lungs could be
examined for any visible signs of damage. Lungs were lavaged as described previously
(see 5.1.1). Again, this fluid was plated to measure the remaining S. aureus within the
lungs. Leukocyte number and type were measured (see below) prior to the cells being
removed from the remaining bronchioalveolar lavaged fluid (BAL). BAL fluid was then
also frozen at -70°C. The lobes of the lungs were then removed and homogenised as
described previously (see 5.1.1).
5.2.6 Leukocyte cell counting and typing
One millilitre of the BAL fluid from control animals was spun down at 13000g for 3
minutes, excess fluid was removed and the pellet was re-suspended in lOOpl PBS.
Crystal violet was added to either the concentrated BAL (controls) or straight BAL
(infected) at a ratio of 1:1 (v/v). Plural fluid was diluted in crystal violet at a ratio of 1:5
(v/v). Ten microlitres of each was added to a haemocytometer. Twenty five squares on
the haemocytometer were counted for number of leukocytes. From this the total number
of leukocytes in the BAL or plural fluid was calculated.
Five hundred microlitres of BAL or 20pl of plural fluid were cytospun onto glass slides.
Once dry, slides were stained with DiffQuik (Gamidor). Slides were then analysed for
number of each type of leukocyte using light microscopy.
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5.2.7 Harvest of lungs for RNA extraction
S. aureus infected rats, 72 hours after inoculation, were euthanized and blood was
extracted as described previously (see 5.2.5). A tracheotomy was performed, the rib cage
was opened and the damage to the lungs was assessed. Lungs were lavaged as descried
previously (see 51.1). The BAL fluid was plated for remaining cfu of S. aureus,
leukocytes were removed from the BAL and the remaining fluid was frozen at -70°C
until needed. Leukocytes were analysed as described previously (see 5.2.6). The lungs
were then perfused with 50ml sterile PBS with Mg2+/Ca2+ (as described in 5.1.1) and
inflated with RNAlater (Ambion). The lungs were removed whole and stored in
RNAlater at 4°C for 24 hours.
5.2.8 RNA extraction
Injured regions of the RNAlater stored lungs were dissected out. One hundred
milligrams of this tissue was homogenised in homogenisation buffer (Qiagen) and the
sample was then added to an extraction column. Total RNA was extracted using the
standard Qiagen protocol with the addition of the DNA removal step (Qiagen). Purified
total RNA was removed from the column using 30pl of 70% ethanol. Total RNA
collected from 2 columns was then pooled and frozen at -70°C until required. Purity of
the RNA was measured via 2100 Bioanalyzer (Agilent Technologies)
5.2.9 Analysis software used
Initial analysis of the raw data was carried out using Affymetrix software to normalise
the data (U34 gene chip algorithm, see appendix i for a guide to how this algorithm
works). GeneSpring (Agilent Technologies) was used to carryout rough analysis of the
data (see appendix i for a guide to how GeneSpring works). This confirmed that the data
was normally distributed. All further analysis was carried out using Microsoft Excel.
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5.3 MMC4 monoclonal antibody's antigen analysis specific techniques
5.3.1. Solubilization of homogenates in CnEg
Homogenates from kidney, lung, intestine and thymus were incubated overnight in
various ratios of mg protein to mg C|2E8 (1:1, 1:5 and 1:10). The solubilized
homogenate was then ultra-centrifuged at 500,000g for 10 minutes to remove any Ci2E8
insoluble fragments. Soluble supernatant (here after referred to as the 500,000g
supematent) were then tested for remaining MMC4 reactivity by ELISA based dot blot.
5.3.2 Immuno-precipitation with Dynabeads1'
(See figure 4 for an overview) Pan anti-mouse IgG Dynabeads1® (Invitrogen) (4 x 106
beads) were incubated with either lOOpl hybridoma supernatant MMC4 antibody or a
control non-specific IgG2a antibody (Stratech Scientific Ltd) for 30 minutes at 4°C with
rotation, allowing the antibody to bind to the anti-mouse IgG antibody bound to the
beads. The coated Dynabeads® were washed three times with PBS with Ca2+/Mg2+ to
remove excess unbound antibody. Then the 500,000g supernatants were added to the
beads (see table 8 for the amount of protein added to the Dynabeads"1). The beads and
samples were incubated at 4°C with rotation for 2 hours to ensure maximum antigen
binding to the MMC4 antibody. The beads were washed with PBS with Ca2+/Mg2+ five
times and bound proteins were removed from the Dynabeads" by incubation with 50|iil
SDS-PAGE sample buffer without mercaptoethanol (containing Tris-HCl (62.5mM pH
6.8), glycerol (20% v/v) and SDS (2%w/v)) at 95°C for 4 minutes. The sample buffer
plus proteins were then loaded (20pl per well) and run on 6 or 8% acrylamide gels (see
5.1.5.). A control of Dynabeads® with no antibody bound was also incubated with
kidney 500,000g supernatant to check for non-specific binding to the Dynabeads®.
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Figure 4: An overview of the selection of the MMC4 antigen using Dynabeads
Key:
* Y 4) (4




Page 60 of 205






Table 8: Amount of protein from various organs required to be added to the Dynabeads®
to enable the MMC4 antigen band to be visible via SDS-PAGE electrophoresis.
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5.3.3. Immuno-depletion ofMMC4 antigen from solubilized homoeenates
(See figure 5 for an overview) MMC4 Monoclonal antibody was attached to Pan Anti-
mouse IgG Dynabeads® (4 x 10(' beads) as described above (5.3.2). Kidney 500,000g
supernatant was incubated in four successive rounds of Dynabeads'". After each
incubation, lOOpl of the remaining supernatant was removed and replaced with lOOpl
PBS (without Ca2+/Mg2+). The supernatants removed were all diluted to the same protein
concentration and tested for MMC4 reactivity via an ELISA based dot blot as described
previously (5.1.4). Proteins bound to the Dynabeads® were removed as described above
and run on 6 or 8% SDS-PAGE gels.
5.3.4. Trypsin digestion
Candidates for the MMC4 antigen were cut out of the gel using a sterile scalpel and
stored at -20°C until needed. SDS was removed from the gel piece via 3 incubations
with NH4HCO3 (0.2M) in 50% acetonitrile (ACN) at 30°C. The protein was then
reduced via incubation with DTT (20mM with NH4HCO3 (0.2M) and 50% ACN) at
30°C.
After washing with NH4HCO3 (0.2M 50% ACN), the cystines were alkalated in
iodoacetamide (50mM in NH4HCO3 (0.2M) 50% ACN) at room temperature in the dark.
The gel piece was then washed in 20mM NH4HCO3 and 50% ACN. All water was then
removed from the gel pieces via incubation with 100% ACN. Excess ACN was removed
and the gel pieces were allowed to dry (increases the probability of trypsin entering the
gel and therefore optimises protein cleavage). One microlitre sequence grade trypsin (in
50mM NH4HCO3) (Promega) was added to the gel pieces and stored at 4°C until the gel
pieces swelled and then pieces were transferred to 30°C overnight to digest the protein.
The digestion mixture was then agitated (vortex 1 minute) and spun for 20 minutes at
13000rpm to remove remaining peptides from the gel.
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Figure 5: Immuno-depletion of MMC4 antigen from solubilized kidney homogenate.
Homogenate was incubated with five successive rounds of Dynabeads® (coated with
MMC4 antibody) as described. The same technique was used for other organs; however
different initial and final protein concentrations were used for each organ.
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Trypsin digested proteins were then processed via a Voyager DE STR MALDI-TOF
mass spectrometer (Applied Biosystems) or via liquid chromatography mass
spectrometry and molecular weight fingerprints obtained were analysed using SwissProt
Tr-EMBL. MALDI-TOF, liquid chromatography mass spectrometry and SwissProt Tr-
EMBL analysis were carried out by Dr. A. Cronshaw (see 7.1.1.1, 7.1.1.3 and 7.1.1.2
respectively for a description of how these techniques work).
5.3.5 Aminopeptidase N functional assay
Aminopeptidase N (APN, 2.5pil) (Calbiochem) was incubated with 5pg L-Alanyl-p-
nitroanlilde (L-Ala-pNA) (Calbiochem) for 6 minutes. At 1 minute time points, the
optical density of the mixture was measured at 405nm. APN cleaves the N-terminal
alanine from L-Ala-pNA. As this occurs the colour of the solution shifts from yellow to
blue, therefore increasing the reading at 405nm. The rate of L-Ala-pNA breakdown by
APN was measured with and without the MMC4 Monoclonal antibody, with the non¬
specific IgG2a antibody (Stratech Scientific Ltd) and without APN. Controls of just
APN and just TBS (used to dilute samples) were also tested.
5.3.6. Macrophage isolation
Macrophages were isolated from the lungs of healthy, male, SPF, SD rats between 300
and 350g in weight. Rats were euthanized via a lethal dose of anaesthetic as previously
described (5.1.1). Lungs were removed from the rat and lavaged with buffered saline
without Ca2+/Mg2+. Macrophages were removed from the lavage fluid via centrifugation
at 300g for 6minutes and resuspended in 1ml TBS with Complete® protease inhibitors
added. The macrophages were then washed three times by centrifuging at 300g for 6
minutes and re-suspended in TBS with Complete® protease inhibitors added. After the
second wash, lOpl of macrophages suspended in TBS was removed to be counted using
a haemocytometer and crystal violet to visualise the cells. After the final wash, cells
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were re-suspended to a concentration of lOxlO6 per ml in TBS with Complete® protease
inhibitors added.
5.3.7. Deglycosvlation of N-linked glvcans
Twenty microlitres N-Glycosidase F (Roche) was incubated with 10pg APN for 1 hour
at 37°C. Fifteen microlitres was then added to Dynabeads® coated with MMC4
monoclonal antibody as described previously. Dynabeads® were incubated with the N-
glycosidase F, APN mixture for 2 hours at 4°C with rotation, the Dynabeads® were
washed to remove unattached proteins and bound proteins were removed as described
previously. APN, APN plus N-glycosidase F, APN plus Dynabead® incubation and APN
plus N-glycosidase F and Dynabead purification, all having had a 1 hour 37°C
incubation, were run on a 10% acrylamide gel. The remaining 15pl of the overnight N-
glycosidase F, APN mixture was diluted to a total volume of 200pl in TBS and tested
for MMC4 reactivity via ELISA based dot blot (5.1.4).
5.3.8 Deglycosylation ofO-linked glvcans
0-1 inked glyeans were removed (as per the manufacturers' guidelines) using O-
glycosidase (Roche). Briefly, O-glycosidase was added to APN and then heated to 37°C
overnight. Samples were then tested for remaining MMC4 reactivity via ELISA based
dot blot (5.1.4) or Dynabead purification (5.3.2) followed by SDS-PAGE gel separation
(5.1.5). Controls of APN with no O-glycosidase and O-glycosidase by itself were also
tested.
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5.4 MMC6 antigen analysis techniques
5.4.1 Proteinase K treatment of lung homogenate
Lung homogenate corresponding to 9mg protein was incubated with 2mg proteinase K
(stock solution is 20mg/ml in lOmM Tris-Cl pH7.5) (Qiagen) for 16 hours at 37°C with
rotation. Controls of lung homogenate (37°C and 4°C) and proteinase K (37°C) were
also incubated overnight. Half of each sample was spun at 500,000g for lOminutes
(Optima TLX ultracentrifuge, Bechman) to separate the soluble and insoluble fractions.
The pellet was re-suspended in 0.5 ml TBS. The un-separated, the 500,000g supernatant
and the 500,000g pellet samples were all tested for remaining antigenicity to MMC6
monoclonal antibody via an ELISA based dot blot as described above (5.1.4)
5.4.2. Sodium carbonate treatment of lung homogenate
Lung homogenate was tested to see if the MMC6 antigen was a membrane protein via
ultracentrifugation at 500,000g (which causes membranes to move to the pellet)
followed by ELISA based dot blot. The membrane pellet was then treated with 0.1M
(pHll) sodium carbonate for 1 hour on ice to remove peripheral proteins from the
membrane. The treated pellet was then spun again at 500,000g, causing integral
membrane proteins to be in the pellet still and peripheral membrane proteins to be in the
supernatant. Lung homogenate, and the pellet and supernatant at each stage were all
tested so that the location of the MMC6 antigen could be determined.
2.4.3 Solubilization of tissue homogenate for antigen purification
Homogenates from the 300g centrifugation were incubated with various ratios of
detergents to total protein concentration for 18h at 4°C (see table 9 for a list of
detergents used and at which ratios). Retention of antigenicity was checked via an
ELISA based dot blot (as described in 5.1.4). Samples were then spun at 500,000g for
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NP-40 1 1, 1 5, 1 10 Yes Yes
Triton x-100 1 1, 1 5,1 10, 1:20, 1:50 No Yes
Dodecyl mactoslate 1 1, 1 5,1 10 Yes Yes
SDS 1 1, 1 5,1 10 No Yes
Mega 8 1 1, 1 5,1 10 Yes Yes
Octyl-R-D-glucopyranoside 1 1, 1 5,1 10 Yes Yes
c,2e8 1 1, 1 5, 1 10 No Yes
ci2e9 1 1, 1 5, 1 10 Yes Yes
Cholic acid 1 1, 1 5,1 10 Yes Yes
CHAPS 1 1, 1 5,1 10 Yes Yes
Table 9: Ratios and conditions of detergents that were used for solubilization of lung
membranes without destroying MMC6 antigenicity.
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10 minutes to pellet the insoluble fraction The insoluble pellet was re-suspended in an
equal volume of TBS and together with the detergent soluble fraction (hereafter called
the 500,000g supernatant) was tested for reactivity of the Monoclonal antibody's via
ELISA based dot blot. Controls of unsolublised 300g homogenate, 500,000g pellets (no
detergent) and 500,000g supernatants (no detergent) were also tested.
5.4,4. Mechanical disruption of lung cell membranes
One hundred microlitres of homogenate were sonicated for five one-second bursts with a
one second rest between bursts on ice. Confirmation that the cells were broken was
carried out microscopically. Alternatively, organ homogenates were further
homogenised at 30,000rpm for 5 minutes on ice.
With both methods, samples were then spun at 500,000g for 10 minutes to pellet the
membrane insoluble fraction. Supernatant and pellet were then tested for remaining
antigenicity via ELISA based dot blot as described previously (5.1.4). Alternatively the
30,000rpm homogenate was spun at 13,000g for 5 minutes to remove the larger tissue
fractions and the remaining supernatant was also measured for remaining antigenicity
via ELISA based dot blot.
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6. Global gene analysis as a method to identify novel alveolar epithelial
markers
6.1 Introduction
As already discussed, to produce a biomarker specific for an injury, first the injury has
to be well studied. This increases the chance that the potential biomarker is linked
directly to the disease being studied and is not just a general marker of injury. Global
gene analysis is one way to do this, either by taking repeated samples at different time
points (to monitor the change in gene expression over time), or by taking a snap shot of
the change based on previous knowledge of the disease being studied.
It was decided to see how useful global gene analysis would be in a rat model of S.
aureus induced pneumonia which had previously been established in our laboratory
group. This model was chosen for two reasons:
1) The limited budget for Affymetrix chips meant that my sample size would have
to be small and it was thought that I would be able to control and limit outside factors
better with an animal model.
2) The model had already been partially characterised within our laboratory group,
and had shown a decrease in AETI cells, but an increase in AETII cells at 72 hours post¬
infection.
The established change in AETI and AETII cell numbers meant that we could also
analyse the data for potential markers for these cell types.
Hypotheses of this study were:
la) Global gene analysis of RNA from S. aureus injured rat lungs can further
characterise the 72 hour S. aureus model of pneumonia,
lb) An animal model of 72 hour S. aureus injury to the lungs could be used to
identify new biomarkers of the alveolar epithelium using Affymetrix U34 gene
chips.
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6.1.1, U34 Affymetrix gene chip
The U34 Affymetrix gene chip has probes for 8740 different proteins found in the rat.
For each protein there are 22 DNA probes, which are paired. Eleven probes are exact
matches for the copy RNA and 11 are single base pair mismatches. Figure 6 shows
cartoon representation of a chip to explain the probe layout. As the mRNA is copied (via
reverse transcription into copy DNA and then transcription into copy RNA) biotin
labelled nucleotides are added to the mix so that the resulting copy RNA is biotin
labelled. The copy RNA, along with control biotin labelled RNA, is allowed to hybridize
to the chip for 18 hours prior to the chip being read. The whole chip is scanned and then
using the control markers that were added to the RNA a grid is laid over the whole chip.
(The control RNA binds to the outside of the chip making a checkerboard
positive/negative pattern allowing the grid to be accurately placed). The absorbance for
each probe is recorded and then, using an algorithm designed for the chip the 11
matched probes and the 11 single mismatched probes are compared and a value is
assigned for the gene.
6.1.2. Analysis of results
As the model of pneumonia is already known to cause an influx of leukocytes both 24
and 72 hours after instillation of S. aureus, at 72 hours it was expected that there would
be a change in the levels of expression ofmany of the genes. Therefore, before starting
to analyse these results, a stratagem was required which would allow handling of this
data and to draw a finite finishing point for each question to be addressed. Figure 7 is a
flow diagram overview of how I intended to manage this problem.
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Control RNA hybridised to the
Figure 6: Cartoon representation of part of an Affymetrix U34 gene chip. Control probes
are arranged around the edge of the chip to allow a grid to be overlaid after hybridization.
This allows the computer to work out which gene is where. The 11 probe pairs for each
gene are arranged in blocks with the 11 complete matches of 25 base pairs on one row and
the single base pair mismatch on the row underneath. (More recent types ofAffymetrix
chips have abandoned this format in favour of probes being placed in a random pattern
across the whole chip).
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72 hour infected animals
y
Analysis of BAL




Analysis in Excel/ by hand
Remove genes that remained the
same/ had very low signals both
before and after treatment
Analyse grouping to see if any
particular pathways/ are up
regulated/down regulated in this
injury model
General trends in all the data
Group genes up- and down-
regulated via a literature search
using Omniviz
Figure 7: Proposed method for data analysis from the Affymetrix U34 gene chips after
injury with S. aureus
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6.2. Results
6.2.1. Visible injury to the lung
72 hours post S. aureus instillation, rats were harvested and the lungs examined for
injury. Figure 8 part i) shows a typical set of lungs from an injured animal, showing the
visibly grey area typically associated with necrotic tissue. Figure 8 part ii) shows the
same set of lungs after perfusion, demonstrating that the injured region of the lungs is
still visible, even after perfusion. The injury was typically to the left lung lobe (green
circle).
6.2.2. Protein analysis of bronchioalveolar lavaged fluid
Figure 9 shows that a 1.6-fold increase (P=0.0026, F=0.2614) in protein in the BAL of S.
aureus-treated lungs compared to PBS-treated lungs 72 hours after treatment. This is the
same increase that was found by Clegg et al (2005). ELISA based dot blots for RTI40 (a
proposed AETI cell marker) showed no change in free RTI40 in the BAL after treatment
(data not shown), as was found by Clegg et al (2005).
6.2.3. Leukocyte levels in the bronchioalveolar lavaged fluid
BAL from S. aureus-treated lungs had a 2.6-fold increase (P=0.386, F=0.2676) in
leukocytes compared to PBS-treated animals. This value is very similar to the 2.5-fold
increase that was found by Clegg et al (2005).
The above information suggests that the injury obtained is similar to that of Clegg et al
(2005). From this it can be predicted that if frozen sections of these lungs (not possible
as they have been fixed in RNAlater) were studied, similar findings of increased
numbers of AETII cells in long lines lining the alveoli and a decrease in the numbers of
AETI cells would be observed.
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Figure 8: Lungs of a S. aureus-treated rat 72 hours after inoculation, i) Lungs before
perfusion, with characteristic 'grey' area where lungs are damaged (green circle) in
comparison to the healthy lung (blue circle), ii) The same set of lungs after perfusion
showing that the injury is still visible after perfusion (green arrow).
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Figure 9: BAL fluid collected from rats 72 hours post instillation with S. aureus showed
an increase in protein levels of 1.6-fold compared to PBS-treated rats. (P=0.0026,
F=0.2414).
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6.2.4. RNA extraction
Total RNA was extracted from approximately lOOpg sections of the injured regions of
the lungs. Control RNA was extracted from tissue samples obtained from the left lobe of
the control lungs. This lobe was chosen as this was where S. aureus instillation typically
caused an injury. Collected total RNA was tested for quantity and quality via
measurements of the absorbencies at 260 and 280nm (table 10) and also by continuous
measurements of the absorbance of the solution (figure 10). S. aureus-treated lungs all
had more total RNA than the control PBS-treated lungs; this could be due to increased
numbers of cells within the lung or cells within the lungs being more active.
Collected total RNA was used as a template for making copy DNA, which was used as a
template for making biotin labelled copy RNA. This labelled RNA was added to
Affymetrix U34 Chips as per the manufacturer's guidelines. The making of copy RNA
and processing of the Affymetrix chips was carried out by Dr. P. Dickinson (Scottish
GTI). Figure 11 shows a section from a typical injured and a control chip. Raw results
for all 6 chips are enclosed on a compact disk at the back of this thesis.
6.2.5. General analysis of the data
Initially I used GeneSpring to analyse my data. Figure 12 shows a basic representation
of all the genes, showing average control vs. average injured values (log scale). This
shows that a) the data is approximately normally distributed (once in log scale) and b)
that although the majority of genes do not change (i.e. are between the 2 fold green
lines) a large number of genes do have a change in the level of RNA collected. A large
proportion of the genes have a low expression (blue dots on figure 12), suggesting that
these genes are just background noise and further analysis will have to be done with
these removed.
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Sample Total RNA extracted
(pg)
Ratio 260:280nm
Control 1 29.88 1.52
Control 2 21.2 1.47
Control 3 15.6 1.53
Treated 1 49.5 1.48
Treated 2 66.2 1.51
Treated 3 81.6 1.48
Table 10: Total RNA extracted from approximately lOOpg of each set of lungs. Ratio of
absorbencies at 260nm and 280nm is given as an indicator of the purity of each sample.
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Figure 10: Spectra of RNA absorbencies found using the 2100 Bioanalyser.
Machine was normalised using a protein ladder (a). RNA from PBS-treated lungs
are shown on (b-d), (e-g) are RNA from S. aureus-treated lungs, (h) is an example
of RNA where the preparation has gone wrong producing contamination of the
sample. (Figure (h) is a kind donation from Dr. P. Lu)
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Control animal 3
Treated animal 3
Figure 11: Comparison of the same area of the U34 Affymetrix gene chip which copy
RNA from a control lung (top) and 72 hour post S. aureus instillation lung (bottom)
have been hybridized. Note the control RNA hybridised to the side, which forms the grid
for alignment (blue arrow). Green box surrounds a probe set for a gene that is decreased
72 hours after S. aureus injury.
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Treatment type Control (raw)
X-axis LindaF Rat Lung (Default Interpret...
Y-axis LindaF Rat Lung (Default Interpret...
Colored by: LindaF Rat Lung. Default Inte
Gene List: all genes (8799)
Figure 12: Gene Spring representation of all the genes on the Affymetrix IH4 Chip.
Graph shows that the majority of genes do not have large changes in the level of
expression (between the 2 fine green lines). However, there are still many genes that do
have greater than 2-fold changes in the levels of expression (above or below outer green
lines). Graph also shows that a large proportion of the genes have low expression
(coloured blue) which suggests that these genes are turned off.
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For each chip, I found the mean and median reading, the standard deviation (of the
mean) for each chip and the skew of each chip (Table 11). This was to ensure that all 6
chips had approximately the same overall results, so any differences found in one gene
can be attributed to changes in that gene's expression, rather than being due to the chips
having a higher or lower overall expression. In general, I found that there were no big
differences between each chip. Therefore, any changes in a genes expression found
between the two treatments can be attributed to a specific change in that genes
expression, and not general variation between the chips.
Perceived 'housekeeping' genes were investigated, to see if these changed after the
injury (Figure 13). Actin, Hexokinase and 5s RNA (except for one reading) remained
the same, while GAPDH (another housekeeping gene) changed. This is not unusual in a
model such as this (P. Dickinson, personal communication) as there is an influx of
different cells into the lung during the course of the treatment and the cells present are
also undergoing changes. GAPDH has also been shown to change in other injury
models, which raises questions about its perceived use as housekeeping gene.
Overall 680 genes increased in expression 2-fold or greater (7.7% of total number of
genes) and 1055 decreased 2-fold or greater (12% of total number of genes). Figure 13
shows that the number of genes that were significantly increased/decreased were 67 and
197 respectively (0.76% and 2.25 % respectively). Approximately a third of both the
significantly increased and decreased genes found were for gene sequences that are for
predicted/estimated genes based on the rat genome. As no known protein is ascribed to
these sequences, it is impossible to find out what functions these potential genes have,
therefore I have excluded them from further analysis of gene functions.
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Treatment PBS 1 PBS 2 PBS 3 S. aureus 1 S. aureus 2 S. aureus 3
Mean (rfu) 143.88 141.01 140.64 151.65 156.86 149.70
Standard deviation
(rfu) 392.08 369.71 370.27 443.75 485.78 430.80
Median (rfu) 31.30 29.80 27.80 23.00 26.40 25.80
Skew 0.86 0.90 0.91 0.87 0.81 0.86
Table 11: Basic statistics on the individual Affymetrix chips. The skew shows that as
predicted, the data is not normally distributed prior to logging of the data. However the
amount of skew is approximately equal for each chip. This also shows that a large
number of the genes are not turned on. The mean, median and standard deviation are
showing that the individual chips are similar with regards to intensity of readings.
Page 82 of 205
Treatment PBS 1 PBS 2 PBS 3 S. aureus 1 S. aureus 2 S. aureus 3
GAPDH 483.76 498.55 511.31 822.35 1149.86 1194.83
Actin 2218.6 2047.05 2169.23 2004.26 2712.5 2359.18
Hexokinase 56.83 70.86 55.56 33.23 46.86 73.66
5s RNA 38.4 32.7 30.9 50.2 32.3 37.3
Table 12: Table of commonly used 'housekeeping' genes. Table shows that, depending
on which gene you chose, either the chips are standardised for loading or they are not.
Three of the housekeeping genes are approximately standardized for loading. GAPDH
RNA levels increase approximately 2 fold 72 hours after S. aureus instillation. Other
global gene analysis studies have also shown that levels of GAPDH change after
different insults.
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Increase 2 fold Decrease 2 fold Remaining genes
Genes on chip 680 1055 7005
F>0.05 478 (343) 919(618)
F>0.05 P<0.05 275 (199) 667(460)
F>0.05 P<0.01 170(127) 462 (316)
F>0.05 P<0.001 67 (49) 197(125)
Table 13: Gene changes, as found on the U34 Affymetrix Chips, within the lung 72
hours after S. aureus instillation. F values refer to the number of genes that have equal
variance. P values refer to the number of genes with a probability less than 0.05,0.01 or
0.001 using a Student t-test, assuming 2 tail distributions and equal variance. As
expected large numbers of genes were found to change, interestingly, due to the influx
of leukocytes it was expected that there would be more genes increasing in expression
than decreasing, when the opposite was found here.
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6.2.6. Changes in known alveolar epithelial type II cell markers.
Proteins that are known to be found on Type II alveolar epithelial cells (I.E. table 2)
were searched for on the Affymetrix chip. Table 14 shows all the genes that were
present on the chip, with their corresponding changes after treatment. Firstly, not many
of the genes were on the chip; however, of those that were, all bar three had less than a
two-fold increase in mRNA expression. In fact some seemed to decrease in expression,
possibly indicating that, although there are more type II cell-like cells within the
repairing alveoli, these cells could possibly not be acting as 'normal' type 11 cells.
The three genes that did have greater than two-fold increase in mRNA were C3, MMP-7
and manganese superoxide dismutase, all of which are also found to be expressed by
macrophages, which, at this time point after injury, are already known to be in the lungs
in greater quantity than in uninjured lungs, suggesting that this could be a possible
reason for these increases.
Surfactant proteins A and D were found to increase slightly, suggesting that there could
be an increase in type II cells. However, alkaline phosphatase (an enzyme found in the
lamellar bodies of type II cells (Edelson, 1988)) remained constant. Four out of five P-
adrenergic receptors (which aid surfactant secretion (Fabisiak, 1987, Ewing, 1992))
actually decreased in expression, which would again suggest that the type II-like cells
are not functioning as 'normal' type II cells.
Due to the amount of evidence suggesting that the type II like cells are not expressing
the full range of type II cell mRNA (and therefore proteins) and because the fold
changes of the known type II cell genes that did increase did not do so by much, I
decided to not use this model to identify novel type II cell associated proteins.




increase F= P= Mean StDev Mean StDev
SP-A 1.24 0.24 0.03 3256.17 141.39 4045.00 384.42
SP-D 1.71 0.21 0.02 1618.83 180.51 2765.17 524.58
Cathepsin H 1.83 0.01 0.00 844.57 3.55 1543.97 52.45
B-adrenergic receptor 1.48 0.87 0.02 83.20 11.75 123.07 13.38
B-adrenergic receptor 0.93 0.41 0.91 16.17 14.32 15.00 7.25
B-adrenergic receptor 0.37 0.16 0.04 130.77 46.62 48.17 13.86
B-adrenergic receptor 0.18 0.44 0.00 54.03 7.92 9.83 4.20
B-adrenergic receptor 0.37 0.05 0.03 118.33 39.81 43.97 6.23
annexin II 1.28 0.63 0.12 1211.63 167.90 1550.00 248.71
Alkaline phosphatase 0.88 0.29 0.11 301.30 11.53 265.37 28.23
Alkaline phosphatase 1.02 0.53 0.80 2294.60 188.20 2351.90 314.02
APN 1.07 0.08 0.86 151.17 19.73 161.73 94.48
APN 1.48 0.95 0.48 107.20 82.99 158.33 79.26
AQP-1 0.94 0.58 0.91 14.03 6.37 13.17 10.01
C3 3.56 0.01 0.00 161.27 3.76 573.47 45.84
C4 1.00 0.79 1.00 839.97 611.20 839.67 755.84
MMP-7 2.13 0.26 0.23 10.53 5.33 22.47 13.76
TIMP-2 1.65 0.03 0.17 766.27 512.57 1264.40 66.56
TIMP-3 0.19 0.22 0.01 602.53 187.00 116.33 66.16
Mn Superoxide dismutase 2.11 0.05 0.04 61.93 6.33 130.57 37.82
Table 14: Fold increase in mRNA for proteins that are known to be associated with
AETII cells. Other proteins known to be associated with AETII cells that are not listed
here are either a) not on the chip or b) general cell proteins (such as cyclins, and
housekeeping genes)
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6.2.7. Changes in known AETI cell specific markers
Proteins known to be found on AETI cells (described previously in table 1) were
searched for on the gene chip (table 15). As with AETII cell associated genes, not all
known AETI cell associated genes were on the U34 Affymetrix®' chip. The one protein
known to be specific for AETI cells within the lung, RTI40, is on the chip however. This
gene, as expected, did have a reduction in the levels of expressed mRNA, but the
decrease was only of 1.4-fold, and the result was not significant. This brings into
question the use of this method to assess the number of the cells within the lung.
Caveolin, AQP-5, RAGE and eotaxin did however all decrease by over 2-fold (eotaxin
and caveolin decreased greater than 5-fold). Ideally, as RTI40 decreased by 1.4-fold, I
would carry on searching for novel proteins associated with AETI cells by using a
decrease in mRNA expression of 1.4-fold or greater. However, using this thresh hold
produced a vast number of proteins to be investigated. I therefore decided to look at
proteins with a mRNA expression decrease of 2-fold or greater, as these would also give
me proteins where the decrease in expression was more likely to be detected via
immunohistochemistry and also gave me a more manageable number of proteins to
investigate.
6.2.8. Potential AETI cell markers
Genes that could potentially be AETI cell markers were then searched for from the
entire U34 Affymetrix gene chip results using the following criteria:
1) The level of expression in the normal lung was over 500 units of absorbency (i.e.
the gene was turned on in normal conditions)
2) The level of expression decreased by 2-fold or greater in animals 72 hours after
the S. aureus insult
3) The decrease in the expression was significant using Student t-test, after
checking that the standard deviations were similar (F-test).
Page 87 of 205
Treatment PBS S. aureus
fold
decrease
F= P= mean Stdev mean Stdev
RTI40 precursor 1.40 0.946 0.09 700.57 110.62 501.17 104.84
Caveolin 6.54 0.086 0.00 1224.90 159.93 187.20 34.01
Na,K.-ATPase a2 0.48 0.377 0.06 12.47 3.96 26.17 8.25
Na,K-ATPase a2 0.23 0.373 0.17 0.60 0.10 2.57 2.06
Na,K.-ATPase a2 0.45 0.227 0.06 29.07 3.97 65.07 23.82
Aquaporin 5 2.11 0.08 0.01 688.00 137.66 326.23 29.63
ICAM-1 1.73 0.65 0.01 357.87 51.52 206.73 35.78
ICAM-1 1.62 0.231 0.00 1231.30 70.57 758.97 25.52
connexin 43 0.80 0.564 0.52 4.70 1.57 5.90 2.51
p-glycoprotein 0.25 0.256 0.09 5.90 5.02 23.67 13.10
RAGE 2.23 0.84 0.00 3317.87 325.97 1490.73 68.52
PAI-1 0.18 0.145 0.00 31.10 5.35 169.23 19.08
eotaxin 5.21 0.569 0.01 30.07 7.23 5.77 4.56
GGT 0.22 0.081 0.00 12.73 2.70 56.67 13.13
osteonectin 1.72 0.237 0.02 1515.77 269.04 880.17 98.65
Table 15: Known AETI cell associated proteins decreased in the lung 72 hours after S.
aureus treatment. Other AETI associated proteins not on this list were not on the
Affymetrix U34 chip.
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Using this selection criteria, 89 genes were selected for further investigation (appendix
ii). All these genes were then researched by hand to find main functions of the protein
product, which cells were known to produce the protein and where on the cell the
protein was commonly located (appendix ii).
A large proportion of the genes were found to be linked to the endothelium (endothelial
cells, smooth muscle cells), suggesting that this model of S. awrews-induced pneumonia
also damages the endothelium. (However, bacteria were not found in the blood of any of
the animals, suggesting that the lung air-blood barrier remains reasonably intact).
6.2.9. CD9
Interestingly, CD9, known to be found on macrophages, giant cells, bronchiolar
epithelial smooth muscle cells and found in the alveoli (cell type not specified)
decreased (2.41-fold, p=0.00002, F=0.79). As there was a 2.6-fold increase in the
number of leukocytes (most ofwhich being macrophages, (data not shown)) found in the
BAL from lungs at this time point, I would have expected the levels of CD9 within the
lung to increase. I therefore decided to investigate where in the alveoli CD9 is expressed
to see if this could explain the decrease in CD9 mRNA expression. Frozen sections of
normal lung were stained with an anti-CD9 antibody, MMC4 (a potential AETII cell
biomarker) and RTfio (a potential AETI cell biomarker). Figure 13 shows that the anti-
CD9 antibody is co-localising with the RTI40 antibody and not the MMC4 antibody,
suggesting that CD9 is expressed by AETI cells and not AETII cells.
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Figure 13: Frozen section of
normal lung stained with MMC4
antibody (blue), RTI40 antibody
(red) and anti-CD9 antibody
(green). CD9 staining pattern
suggests that CD9 is expressed
by AETI cells and not AETII
cells.
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6.3. Discussion
The animals that I treated with S. aureus bacteria 72 hours post instillation did have
similar biochemical analyses to those done previously by Clegg et al (2005). This
suggested that I had indeed caused a similar pneumonia injury within the rats via the
instillation of S. aureus as had been previously characterised. The Affymetrix analysis of
the RNA from the injured lungs did, as expected, show a large number of genes to be
either up and down regulated after the injury. Despite the increase in AETII cell-like
cells found within the lung 72 hours post inoculation via electron microscopy and
immunohistochemistry (Clegg, 2005), a corresponding increase in mRNA from AETII
cell associated genes was not found. This further supports the hypothesis proposed by G
Clegg (2005) that the AETII cell-like cells within the lung at this time point are not
functioning as conventional AETII cells. However, the lack of change could also be due
to the proteins having a auto-regulatory loop with themselves to prevent levels of
expressed protein from increasing dramatically, an example of this is surfactant protein-
A. Although auto-regulation could explain why some genes did not have as high mRNA
expression as expected, the number of genes that remained constant suggests to me that
it is more likely that the AETII-like cells within the lung at this point are not all
functioning like AETII cells would be in the normal lung.
Within the group of genes that decreased after S. aureus instillation there were a large
number of genes that are associated with the endothelium (31 out of 89). This was
unexpected as all previous studies of this model of S. aureus induced pneumonia have
shown no injury to the endothelium (as shown by lack of blood serum proteins in the
BAL and the fact that no bacteria were found in the blood). This suggests that either
there is minor damage to the endothelium that the body is able to compensate for or that,
although the endothelium is intact, that these cells have also changed their gene
expression profile due to the S. aureus injury. Further investigation into the extent and
type of damage to endothelial cells caused by the S. aureus induced pneumonia is
therefore required to fully understand these results.
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Within the down regulated group of genes there were also some genes associated with
AETI cells, suggesting that this data set could be used to study AETI associate proteins.
However, there were also some proteins that were found to decrease that were not
expected to. CD9 is known to be associated with most cell types including macrophages
which express CD9 at high levels. As there was an increase in macrophages within the
lungs at 72 hours post-instillation it was surprising to find this protein decreasing in my
data set. Due to this, we investigated the protein further. CD9 has been found to be on
the alveolar surface, but cell specificity for either AETI or AETII cells has not been
shown before. Immunohistochemical analysis of frozen lung sections showed that an
anti-CD9 antibody co-localises with RTI40 antibody but not MMC4 antibody in the
normal lung. This suggests that CD9 is expressed on AETI cells but not AETII cells.
CD9 is a tetraspanin protein (Takeda, 2003) known to have roles in reducing cell
proliferation by binding HB-EGF (a potent soluble mitogen which affects epithelial
cells, fibroblasts and vascular smooth muscle cells) (Makamura, 2000), reducing cell
motility by binding to (31 intergrins (Funakoshi, 2003), affects cell activation,
proliferation, fusion of gametes and apoptosis (Takeda, 2003). CD9 also has an effect of
cell signalling via interactions with PKC and PI4K (Yunta, 2002). Based on this
information CD9 expression by AETI cells is not un-expected as these cells are known
to not be motile, terminally differentiated and non-proliferative, all characteristics that
CD9 aids within the cell. However the lack of CD9 on AETII cells does seem odd based
on the wide spread distribution of the protein. The sections that I stained with the CD9
antibody were from control normal lung were there is not a large turn over of cells. As
the AETII cells are not therefore proliferating or moving as much as they do after injury
1 would have therefore expected these cells to have also been producing CD9. One
explanation for this however could be linked to how AETII cells react in the absence of
AETI cells. In vitro freshly isolated AETII cells, over a period of days, move and
differentiate into AETI-like cells. In vivo the lack of neighbouring AETI cells also cause
AETII cells to start to proliferate, become more motile and differentiate to AETI cells.
From this it appears that AETII cells only retain their morphology when neighboured by
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AETI cells. This suggests that AETI cells produce a molecule that prevents these
characteristics in AETII cells. CD9, with its ability to bind HB-EGF explains one of
these methods. It would be interesting to see if CD9 could cause a decrease in
differentiation and motility ofAETII cells in culture.
Despite CD9 being found on macrophages, making it unsuitable for use as a marker of
AETI cells in BAL from the lung, the specificity of CD9 for AETI cells and not AETII
cells that was found does show that, at least in principle, this method for looking for
novel markers ofAETI cells does work. By looking at the proteins that were found to be
down regulated, but are not known to be in the lung, vascular or nervous system it may
be possible to find other proteins that are currently not known to be associated with
AETI cells. Even if, as in the case of CD9, they prove not to be specific for AETI cells
within the lung, due to the lack of knowledge about proteins that are found associated
with AETI cells', and therefore the cells' functions, any further proteins found to be
associated with AETI cells will increase the knowledge about this cell population.
Global gene analyses in models of injury are very hard to analyse due to the large
number of different genes that change within the organism. Here we used an animal
model in the hope of reducing the number of genes that would change as the animals
would all be in a controlled environment, eating the same food and be given identical
medication, drugs etc. However, even with these precautions there were still a large
number of genes that changed. Many existing packages for sorting data from gene chips
rely on grouping data based on known function/cell type. While these methods may be
useful in interpreting data where the disease is being investigated, when the
investigation is instead into the genes found to be produced by the different cells types
many of these packages fall down. This is due to the packages assigning the protein to a
cell type regardless of the RNA having an increase or decrease in expression. This
meant that if a gene was known to be expressed on one cell type, for example
macrophages, then the gene was assigned to that cell type, regardless of the fact that the
gene expression has decreased, while the number of these cells has increased. I found
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using these databases both time consuming and ultimately a waste of time. This is why I
proposed and eventually used a simpler technique, even though it did in the long-run
prove to be more time consuming to search the literature by hand.
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7. Purification of a rat Til and Clara cell antigen
3.1 Introduction
MMC4, a monoclonal antibody (isotype IgG2a), recognises alveolar epithelial type II
and Clara cells immunohistochemically within the lung (Boylan, 2001). It has therefore
been proposed as a potential marker of injury to these cell types (Boylan, 2001). Despite
proposing the MMC4 monoclonal antibody as a marker of these cell types, the actual
antigen for the antibody is unknown.
The objectives of this study were therefore:
a) to identify the antigen of the MMC4 monoclonal antibody
b) to assess the usefulness of MMC4 monoclonal antibody as a marker of AETII
and Clara cell injury
MMC4 monoclonal antibody was raised via 2 injections of an enriched AETII cell
preparation from SD rats into female BALB/c mice. The resulting sera were screened for
reactivity to rat AETII cells on frozen sections of the lung. Hybridomas were then re-
cloned three times to ensure a single clone was in the preparation. Reactivity to the
MMC4 monoclonal antibody was also found on proximal tubule epithelial cells of the
kidney, on villus epithelial cells of the intestine (Boylan, 2001) and in the thymus (cell
type undetermined (Boylan, thesis)). Within the lung, the MMC4 monoclonal antibody
binds to the apical surface of both AETII cells and Clara cells (Clegg, 2005, Boylan,
2001) via immunohistochemistry. The MMC4 antigen is an integral membrane protein
as shown by Triton X-l 14 phase separation and the ability of Proteinase K to obliterate
antibody binding to lung tissue (Boylan, 2001). Boylan et al were unable to purify the
MMC4 antigen via Western blotting, and they showed that this was due to the SDS in
the gel buffers, as SDS was shown to reduce MMC4 monoclonal antibody binding to
lung homogenate via ELISA based dot blot (Boylan, thesis).
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Clegg et «/(2005) recently showed that the MMC4 antigen is expressed on freshly
isolated type II cells in vitro but over time the expression is lost as the type II cells trans-
differentiate into type I-like cells. However, MMC4 monoclonal antibody binding is
retained after some other type II cell markers (RTII70) are no longer recognising the
cells, and after some type I cell markers are expressed (RTI40). Due to the binding
pattern of the MMC4 monoclonal antibody (with regards to organ distribution and also
within the cell), it is thought that MMC4 monoclonal antibody recognises a novel
protein (Boylan, 2001).
7.1.1. Investigation method.
Validating the MMC4 antibody as a biomarker required investigations into two different
areas of the antibody:
1) How useful is the MMC4 monoclonal antibody as a marker in an injury model?
(Including is an invasive technique required to obtain a measurable sample?)
2) What is the MMC4 antigen?
To investigate the usefulness of MMC4 antibody as a marker it was decided to look at
MMC4 levels in the BAL fluid as well as in the lung. To cause an injury to the lungs it
was decided to use two different strains of Staphylococcus aureus, 8325-4 and 8325-4
PLs. As previously described (see 6.1.1) S. aureus was known to cause an injury to the
alveolar epithelium 24 hours post instillation, typically a localised denuding of the
basement membrane of AETI and AETII cells. An in vitro study into different
fibronectin binding proteins of S. aureus showed that strains containing the PLs vector
were less likely to be phagocytosed than those that did not have this vector (Franklin,
thesis). As the S. aureus 8325-4 PLs bacteria would therefore survive longer within the
lung it was predicted that there would be greater damage to the epithelium with this
strain than the 8234-5 strain. It was therefore decided to see if the MMC4 monoclonal
antibody could firstly recognise a change in its antigen in the BAL fluid and secondly if
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the antibody was sensitive to recognise a difference in the levels of MMC4 antigen
within the BAL between the two treatments.
As Boylan had already been unable to purify the MMC4 antigen via western blot (due to
SDS denaturing the protein), it was decided to try to purify the antigen without the
addition of any reducing agent. Dynabeads® were suggested as a method of separating
the antigen from other proteins of the cell. Dynabeads® are antibody coated beads,
which hold no charge. Antibodies of choice can be attached to the beads and then they
can be used to bind proteins. Once a magnet is placed near the tube containing the beads
the beads become charged and move towards the magnet, enabling any liquid in the tube
to be removed. Attached proteins and antibodies can be removed from the Dynabeads®
via heating in the presence of SDS-PAGE sample buffer.
Once the protein has been purified and separated from the antibody via SDS-PAGE, I
planned to analyse the protein via MALDI-TOF mass spectrometry (MS) analysis.
7.1.1.1. MALDI-TOF Mass Spectrometry
MALDI-TOF stands for Matrix-Assisted Laser Desorption/Ionization-Time of Flight.
Figure 14 shows a general diagram of how MALDI-TOF MS machines work. Sample
proteins to be tested are first broken down into smaller peptides via enzymatic digestion
(usually with trypsin). The peptides are then co-crystallised onto a surface with a
compound of high molecular weight (normally an organic acid which weakly absorbs
UV rays) on a cassette. The cassette is loaded into the MALDI-TOF machine and a UV
laser is then used to vaporise the matrix and therefore the peptides of interest as well. At
the same time the matrix compound becomes an ion donor/acceptor allowing the
peptides to become charged. The vaporised peptides then travel down a tube to a plate
reader. The time it takes for a peptide to travel to the reader is dependent on the size and
charge of the peptide. As proteins when broken down by trypsin digestion will form
peptides of various lengths and number the resulting MALDI-TOF spectra obtained
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Figure 14: Principle of the MALDI-TOF mass spectrometer. Peptides (analyte) are
mixed with a matrix medium and dotted onto a cassette. UV irradiation ionises the
matrix, causing the peptides to become charged. Charged peptides move down the fight
tube at different speeds based mainly on weight, but also charge. (Figure adapted from
Marvin, 2003)
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should be unique for the protein in question. Comparison of the peaks obtained from the
spectra can then be compared to other known protein's spectra (through packages such
as SwissProt-TrEMBL, see 7.1.1.2 for how these packages work) to discover what the
protein in question is.
7.1.1.2. MOWSE scores
Databases such as SwissProt-TrEMBL cannot determine exactly what a given protein is,
however they can give a best guess based on the fingerprint caused by the peptides
found during the MALDI-TOF MS. As knowledge of the probability of a 'hit' occurring
is useful in determining if the result is believable or a result of many contaminating
proteins a probability score called MOWSE scores are used (Pappin, 1993). MOlecular
Weight SEarch fragment database scores (MOWSE scores for short) are produced by a
complex algorithm.
To obtain a MOWSE score, the molecular weight of individual fragments after digestion
are required as well as the full molecular weight of the protein being examined. If the
researcher knows the molecular weight of the protein being examined then proteins are
excluded from the search if the database protein weight is more than the specified
molecular weight plus R or if the database protein is less than the specified molecular
weight minus R. R is the specified molecular weight multiplied by the molecular weight
filter percentage (which the researcher specifies) divided by 100. This system allows for
error in the molecular weight found from the actual molecular weight of the amino acid
backbone, for example if the protein is glycosylated.
The MOWSE database therefore has a list of possible proteins based on the protein's
overall weight. The database then compares fragments of these proteins one by one to
the fragments found by the MALDI-TOF MS analysis. If a fragment is found to be of
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similar length to the expected fragment then a peptide score value is assigned to the
fragment. Fragments that are not found in a protein are considered neutral and not
assigned a peptide score value. Peptide score values are assigned based on the
probability of a peptide fragment of that length being found for a protein of that
molecular weight (all values are between 0 and 1). When more than one fragment is
identified for a protein (such as in MALDI-TOF MS analysis) individual peptide score
values are multiplied together. Finally to allow for skew due to large proteins having
many fragments while small proteins do not, the product of the individual peptide scores
(Ps) is multiplied by the molecular weight of the found protein (Fmw), then dividing
50,000 by this value (I.E. MOWSE score = 50,000/(Ps x Kmw)).
This scoring system means that greater weight is given to peptides of unusual weight
(normally the heavier peptides) as they have low initial peptide score values (Pappin,
1993). If however a protein does fragment into many small peptides this technique will
give a possible peptides back, but the MOWSE scores will be lower. In this case looking
at the comparible difference between the top MOWSE score and the next most likely
'hit' gives a better idea as to the probability of the top 'hit' being correct. Overall, the
larger the MOWSE score, the more probable that the protein being proposed by the
database is the same as the protein that you are trying to identify.
7.1.1.3. Tandem mass spectrometry
Tandem mass spectrometry (also called MS-MS spectrometry) covers a wide variety of
different techniques. Basically one type of mass spectrometry is linked to a second type
to give more detailed results than using one method alone would. Figure 15 shows how
the method used in this thesis works. In brief, trypsin digested peptide fragments of the
protein to be identified entered the initial mass spectrometry chamber via nanospray and
then hit by a lazar to cause the particles to become charged. These pass through magnets
which cause a deviation in the particle based on charge. As with the MALDI-TOF mass
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Nanospray
Figure 15: Overview of how the tandem mass spectrometry machine used works. The
lazar excites the incoming peptides, causing them to become charged. The charged
peptides move in different directions due to the magnets. Selected peptides move into
the second chamber where they become further charged due to bombardment with
helium gas. The change in charge is then recorded by a plate reader after, again, passing
though magnets.
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spectrometer the particles also move at different speed based on size. The peptides reach
the first plate reader over a period of time. Every second the computer takes a reading of
the mass, charge and intensity of peptides hitting this plate reader. The three peptides
with the highest intensity are filtered through to the next chamber IF they have a charge
greater then one (I.E. -1,0 and +1 are not allowed through). These fragments then are
further bombarded with helium gas which causes disassociation of the peptides along the
N-C bonds, further charging the peptides. After passing through magnets again the new
charge to mass ration is measured. As with the MALDI-TOF data, the data from the
tandem mass spectrometer is analysed via SwissProt-TrEMBL and MOWSE score are
assigned based on the likelihood of the protein being investigated being the known
protein.
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7.2 Results
7.2.1 MMC4 as a marker ofAETII cell injury
SD rats were instilled with either S. aureus strain 8325-4, S. aureus strain 8325-4 PLs
(both suspended in PBS) or just PBS. 24 hours after instillation rats were euthanized
and BAL fluid and lungs were removed for protein analysis. Table 16 shows the average
inoculums used, which are approximately equal for the two S. aureus treatments, and the
total protein, colony forming units and leukocytes recovered in the BAL fluid. There
was no significant difference found between all three treatments with regards to protein
levels recovered. This was slightly unexpected as a previous study by McElroy et al
8 9
showed that at inoculums 6x10 and 4x10 there was a 3.5 fold and 12 fold increase in
protein levels respectively (McElroy, 1999). The levels of inoculation used were
slightly less than the 6 x 108 used by McElroy et al however, similar results were
expected at this inoculation level.
As expected most of the 8325-4 strain of S. aureus infection had been removed 24 hours
post-instillation. Interestingly there was no significant difference in the levels of colony
forming units of 8325-4 and 8325-4 PLs strains recovered from the lungs; this suggests
that despite the in vitro differences in phagocytosis, there is no difference between these
two strains in vivo with regards to bacterial clearance times. Despite this there was
almost 3 fold more leukocytes recovered from the lungs of rats treated with 8325-4 PLs
S. aureus compared to rats treated with the 8325-4 strain, indicating that the host
response was larger in these animals.
ELISA based dot blots were used to analyse the levels of MMC4 and RTLo reactivity
within the BAL fluid and lung homogenate. MMC4 and R.TI40 levels did not change
significantly within the lung homogenate, however levels did change in the BAL (figure
16). In both cases levels of reactivity did not change significantly between PBS treated
and 8325-4 S. aureus treated animals. Within the BAL samples collected, MMC4
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Instilled Innoculum
size (CFU)






PBS 0.00E+00 3 2.217 ±0.907 0 1208000
8325-4 4.84E+08 4 2.904 ±0.653 1595 9390000
8325-4 PLs 5.32E+08 5 3.061 ± 1.095 2217.5 29210000
Table 16: Levels of bacteria instilled into rats and levels of protein, colony forming
units (CFU) and leukocytes recovered in the BAL. Levels of protein recovered increased
after both S. aureus 8325-4 and 8325-4 PLS treatments compared to the PBS control .
There was however no significant difference with regards to the levels of protein or
remaining cfu found between the two S. aureus strains. There was however an almost 3
fold increase in the number of leukocytes found in the BAL of the 8325-4 PLs infected
animals compared to the 8325-4 infected animals.













Figure 16: Relative densitometry units (RDU) of MMC4 and RTI40 recovered from the
BAL via ELISA based dot blot 24 hours after inoculation of S. aureus strains 8325-4
and 8325-4 PLs
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reactivity increased 4.9 fold (P=0.0012) after S. aureus 8325-4 PLs treatment compared
to PBS alone. RTI40 reactivity also increased in the BAL (3.3 fold), however this result
was not significant (P=0.0537). This suggests that AETII cells are more damaged by S.
aureus induced pneumonia than AETI cells. This was unexpected as AETI cells are
known to be more venerable to damage than AETII cells in general lung injury.
This therefore shows that MMC4 reactivity is detectible in the BAL. It is also possible to
detect changes in the MMC4 reactivity levels after S. aureus injury suggesting MMC4
could be used in a non-invasive manor to measure changes in AETII and Clara cell
numbers within the lung.
7.2.2, Relative amounts ofMMC4 per mg protein
The proportion of the protein that is the MMC4 antigen in each organ was measured as
optical densitometry units (ODU, n=4 with samples run in duplicate) per milligram
protein (n>7, depending on organ) (Figure 17).
The kidney has the highest MMC4 reactivity per milligram protein. This was
unexpected as the antibody was raised against alveolar epithelial type II cells from the
lung and, therefore, it was expected that the lung would have the highest antibody
reactivity. This result does however confirm G. Boylan's earlier finding (Boylan, 2001).
MMC4 antigen was also found in the intestine, thymus and placenta. ELISA based dot
blot shows the liver to have no MMC4 antigen.
7.2.3 Optimisation of Ci?Er solubilization
As the MMC4 antigen was known to be membrane associated (Boylan, 2001) the
cellular membranes needed to be solubilized prior to the MMC4 antigen being purified.
It had previously been shown that C^Eg solubilized cell membranes whilst conserving
the MMC4 antibody's reactivity (Boylan, thesis). Intestine, kidney, lung and thymus
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Kindey Lung Liver Intestine Thymus
Organ
Figure 17: Relative binding of MMC4 Monoclonal antibody to homogenates of various
tissues. Data expressed as MMC4 binding (represented as Optical densitometry units
(ODU)) per mg protein.
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were solubilized in various ratios of protein to C12E8 (mg protein to mg C^Eg) overnight
to find the optimum ratio of protein to detergent for solubilization. Insoluble cell
contents were removed from the samples via ultra-centrifugation. The soluble
supematants were then tested for MMC4 reactivity via an ELISA based dot blot (Figure
18).
In the thymus (Figure 18c) there appears to be some soluble MMC4 antigen before
solubilization with C^Eg, as the negative control (supernatant from the 500,000g spin,
where no C^Eg had been added) shows 16% of the MMC4 reactivity of the positive
control, suggesting that although the majority of the MMC4 antigen is membrane bound
there is a small proportion that can be found free ofmembranes.
Overall, it was found that a ratio of 1 mg protein: 5 mg C^Eg had the maximum
recovery ofMMC4 after solubilization for the intestine, kidney, lung and thymus. As the
liver showed no MMC4 activity before solubilization (figure 17) it was not possible to
find which ratio of C^Eg solubilized this organ best. However, as all other organs were
being solubilized with a ratio of 1:5 (mg protein: mg C^Eg) it was decided to use this
ratio for the liver as well.
7.2,4 Immuno-precipitation of the MMC4 protein from all organs.
Dynabeads1' pre-coated with MMC4 monoclonal antibody were used to select the
MMC4 antigen from C^Eg solubilized homogenates of the intestine, kidney, liver, lung
and thymus. Precipitated antigen was removed from the Dynabeads" via heating in
SDS-PAGE sample buffer, which was then run on 6 or 8% acrylamide gels. Controls of
Dynabeads'1" with a non-specific IgG2a and no secondary antibody were also incubated
with kidney C^Eg soluble homogenates (Figure 19a).
For all 5 organs, once the gel was stained with Gelcode there were 2 protein bands
clearly visible (Figure 19b). The heavier of these, approximately 150kD, are the MMC4































Control 1 Control 2 1:1 1:5 1:10
Treatment








Control 1 Control 2 1:1 1:5 1:10
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Figure 18: MMC4 reactivity
remaining after solubilization
of organs with various ratios
of CnEs. Data is shown as a
percentage of the MMC4
reactivity recovered for the
unsolubilized positive control
(raw homogenate). The level
of MMC4 antigen already
soluble (without adding any
detergent) is also shown
(negative control). 18a and
18b (kidney and Lung) both
show the best recovery of
MMC4 antibody reactivity
with the 1:5 ratio of CnEg.
18c (Thymus) shows an
increase in the amount of
reactivity recovered after
C12E8 solubilization compared
to the positive control, but this
can be explained by some of
the MMC4 being already
soluble within the cells'
cytoplasm (control 2). The
intestine does not have good
recovery of MMC4 reactivity
after C12E8 solubilization
(18d) and the liver does not
show any MMC4 reactivity
under any of these conditions
(data not shown)
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no antibody MMC4 IgG2a MMC4 MW
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!gG2a MW: ~ 150 kDa
Precipitated
Protein Mean MW across
all five organs
= 117kDa
Figure 19: Six percent acrylamide SDS PAGE gel of immuno-precipitated putative
MMC4 antigen and IgG bands for all five organs (19b) and controls using kidney
homogenate (19a). Samples were purified using MMC4 coated Dynabeads. All protein
was removed from the Dynabeads via SDS PAGE sample buffer without mercaptoethanol
and heating and then run on acrylamide gels.
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antibody and the anti-mouse IgG antibody (which comes pre-coated on the
Dynabeads®). The 150kDa band was also found on both the controls. The second band
(approximately 117kDa) found from the samples that had been incubated with MMC4
monoclonal antibody coated Dynabeads® was not, however, found on either the controls
(Figure 19a). This strongly suggests that the second band found is specific binding. It
was noticed that the band was running at slightly different molecular weights in different
organs and that this pattern was repeatable (n=3).
Immuno-precipitation of the MMC4 antigen was also tried from Til alveolar epithelial
cells; however only one band (150kDa, therefore immunoglobulin) was recovered (data
not show). This is thought to be due to there not being enough type II cells added to the
beads. Various numbers of AETII cells were tried up to the entire number recovered in
an isolation. Due to the time, cost in materials and rat and difficulty in isolating AETII
cells from the rat lungs it was decided not to carry on trying to isolate the MMC4
antigen from enriched AETII cells.
7.2.5 Immuno-depletion of the lung and kidney via successive rounds of MMC4 coated
Dynabeads®
To confirm that the 117kDa band found was linked to the MMC4 antigen, a sample of
solubilized homogenate was put through successive rounds of Dynabeads® coated with
the MMC4 monoclonal antibody (kidney and lung only). At each stage a small sample
of supernatant was removed for ELISA based dot blot. The supematants that were
removed were all diluted to have the same protein concentration before being loaded
onto the dot blot manifold. The proteins that were attached to the Dynabeads® were
also removed and run on a 6 or 8% down to acrylamide gel to confirm that there was
still only one unknown band being found and that is was at the correct molecular weight
(kidney only). Figure 20 shows that as the unknown 117kDa protein is removed from









Figure 20: Immunodepletion ofMMC4 antigen from kidney homogenate.
20a) 8% acrylamide gel showing the IgG band (150kDa) and the putative MMC4 band
(130kDa) after 0-4 rounds of Dynabeads purification. The decrease in the amount of
putative MMC4 attached to the beads is probably due to there being less MMC4 remaining
in the sample.
20b) Graph of the results from the ELISA based dot blot showing that the level of MMC4
reactivity is also going down after each round of Dynabeads, suggesting that the MMC4
antigen is being removed from the sample.
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decrease in the level of MMC4 reactivity on an ELISA based dot blot (Figure 20b)
(n=3). This suggests that the unknown protein is either a) the MMC4 antigen or b) a
protein closely associated with it.
7.2.6 Identification of the Putative MMC4 band
The putative MMC4 antigen (from each organ) was excised from the acrylamide gel and
trypsin digested. The resulting peptide fragments were analysed by MALDI-TOF mass
spectrometry (figure 21 shows the raw MALDI-TOF data for each organ) and
SwissProt-TrEMBL was used to find the most likely candidates for the MMC4 antigen.
In all five organs, there was one protein with a high MOWSE score and many proteins
with lower MOWSE scores (figure 22) suggesting that the strong hit is the correct
protein. The protein with the high MOWSE score in each case was rat aminopeptidase N
(APN). Table 17 gives the actual MOWSE scores and the number of masses matched for
each organ. The intestine also had a high MOWSE score for a second protein which
was CD 13, the mouse homolog of APN. This result is not unexpected due to the high
degree of homology between APN in the two species.
Peptides from the trypsin digestion of the kidney were also analysed via tandem mass
spectrometry. The resulting spectra were again analysed in SwissProt-TrEMBL. Again
APN was found to be the most likely candidate for the MMC4 antigen (MOWSE score
1.9 x 107) with 6 of the peptides analysed being from APN. The 6 peptides found are
from various regions of the APN protein (figure 23), suggesting that the protein analysed
is APN and not an unknown protein with a similar domain to APN.
7.2.7. Confirmation that the MMC4 antibody is recognising APN
To confirm that the MMC4 antigen is APN, decreasing concentrations of purified
(>90%) rat APN were tested for MMC4 reactivity on an ELISA based dot blot. Figure
23 shows that the MMC4 antibody is binding to the APN protein, confirming that this
protein is an antigen for the MMC4 monoclonal antibody. The distribution of APN
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Figure 21: Raw MALDI-TOF spectra for
the putative MMC4 antigen immuno-
precipitated from all five organs.
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Figure 22: MALDI-TOF
MOWSE scores found for
the MMC4 unknown protein
using SwissProt-TrEMBL
search engine. Rat APN
MOWSE score is shown by
red arrow on each graph.
Lung, liver and thymus
searches were limited to rat
proteins only. The intestine
search was for all mammals,
mouse APN (blue arrow) is
therefore also a high hit, due
to the level of homology
between the two species.
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Organ MOWSE score Masses matched/ total
number masses entered
into SwissProt-TrEMBL
Lung 1.76 x 10lb 28/50
Liver 3.6 x 101' 30/82
Intestine 5.3 x 10b 11/31
Thymus 4.24 x 1016 28/68
Table 17: Actual MOWSE scores and number of masses matched to aminopeptidase N
from the raw MALDI-TOF mass spectrometry data for the putative MMC4 antigen from
each organ.
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makgfyiskt lgilgillgv aavctiials vvyaqeknrn aensaiaptl pgstsattst
tnpaideskp wnqyrlpktl ipdsyqvtlr pyltpneqgl yifkgsstvr ftcnettnvi
iihskklnyt nkgnhrvalr algdtpapni dttelverte ylvvhlqgsl vkghqyemds
efqgeladdl agfyrseyme ggnkkvvatt qmqaadarks fpcfdepamk asfnittlihp
nnltalsnml pkdsrtlqed pswnvtefhp tpkmstylla yivsefkyve avspnrvqir
iwarpsaide ghgdyalqvt gpilnffaqh yntaypleks dqialpdfna gamenwglvt
yresalvfdp qsssisnker wtviahela hqwfgnlvtv dwwndlwlne gfasyveflg
adyaeptwnl kdlivlndvy rvmavdalas shplsspane vntpaqisel fdsityskga
svlrmlssfl tedlfkkgls sylhtfqysn tiyldlwehl qqavdsqtai klpasvstim
drwilqmgfp vitvntstge iyqehflldp tskptrpsdf nylwivpipy lkngkedhyw
leteknqsae fqtssnewll lninvtgyyq vnydennwrk iqnqlqtdls vipvinraqi
ihdsfnlasa gklsitlpls ntlflasete ympweaalss lnyfklmfdr sevygpmkry
lkkqvtplfa yfkiktnnwl drpptlmeqy neinaistac ssgleecrdl wglysqwmn
nsdnnpihpn lrstvycnai afggeeewnf aweqfrkatl vneadklrsa lacsnevwil
nrylsytlnp dyirkqdats tivsiannw gqtlvwdfvr snwkklfedy gggsfsfanl
iqgvtrrfss elelqqleqf kednsatgfg sgtraleqal ektkanikwv kenkdvvlkw
ftens
Figure 23: Amino acid sequence of aminopeptidase N. Fragments shown in red
represent the peptides identified by tandem mass spectrometry. These peptides are
distributed throughout the entire proteins, decreasing the probability that the SwissProt-
TrEMBL search engine has found a protein with a similar domain to the unknown
MMC4 antigen rather than the MMC4 antigen.














Figure 24: ELISA based dot blot of commercially purified aminopeptidase N. The
MMC4 monoclonal antibody does bind to purified aminopeptidase N, confirming that
this is an antigen for the antibody.
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between organs is close to that which I found with the MMC4 antibody with the kidney
having a far higher level than elsewhere. However, the ELISA based dot blot does not
show MMC4 antigen in the liver (although subsequent analysis via immuno-
precipitation does show it to be present) or brain (data from Boylan, thesis), where APN
has been much studied (Gillespie, 1992, Kunz, 1994). APN has also been found on
macrophages (Ashmun, 1990).
7.2.8. Aminopeptidase N presence on macrophages
Leukocytes were removed from the BAL of SD rats, diluted to contain an equal number
of cells per millilitre and stored at -70°C. Samples were then tested via ELISA based dot
blot for MMC4 reactivity, with varying success (figure 25). To further confirm whether
macrophages express APN in a form recognisable by MMC4 Monoclonal antibody,
frozen sections of lung were stained for MMC4 and CD68, a glycoprotein strongly
expressed in the cytoplasm of macrophages. Tissue from four rats was tested. Elevenor
twelve fields from each animal were captured and the number of macrophages staining
positive for APN was analysed using the MMC4 antibody, (figures 26a and 26b show
typical pictures of macrophages both with and with out MMC4 reactivity). Overall
8.45% (SD=6.94) ofmacrophages counted had MMC4 reactivity. The fact that there are
very few macrophages per tile, and only a small proportion of these are MMC4 positive,
could explain why G. Boylan reported that macrophages were negative for MMC4
reactivity (Boylan, thesis).
7.2.9. MMC4 is not a functional inhibitor of aminopeptidase N
APN is an enzyme that cleaves the N-terminus from other proteins. An artificial
substrate for APN is L-Ala-pNA which becomes blue when the N-terminal alanine is
removed. Commercial APN was incubated with L-Ala-pNA in the presence and absence
of the MMC4 monoclonal antibody and also with an IgG2a not specific antibody for 0-6
minutes and the absorbencies of each solution was measured at 405nm. Figure 27 shows




Figure 2425: MMC4 monoclonal antibody binds weakly to macrophages from the lung.








Figure 26a: Frozen lung section stained with Topro (blue), CD68 (green) and MMC4
(red). Section shows a lung that is negative for MMC4 monoclonal antibody staining
(arrow)
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Figure 26b: Frozen lung section stained with topro (blue) CD68 (green) and MMC4
(red). Section shows a macrophage that is positive for MMC4 monoclonal antibody
staining (Blue arrow), adjacent to a type II cell (green arrow)




























■ L-Ala-pNA S L-Ala-pNA+APN □ L-Ala-pNA+APN+MMC4
Figure 27: APN hydrolysation of L-Ala pNA is not inhibited by the addition ofMMC4
Monoclonal antibody or an IgG2a control, suggesting that the MMC4 binding site is not
the catalytic domain ofAPN.
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that the increase in optical density was not affected by the addition of the MMC4
antibody. The IgG2a control antibody also caused no change in rate of hydrolysis (data
not shown). The MMC4 monoclonal antibody, therefore, does not affect the removal of
N-terminal amino acids from L-Ala-pNA. This suggests that the MMC4 monoclonal
antibody does not bind to the active site or L-Ala-pNA's binding site of APN.
7.2.10. MMC4 monoclonal antibody does not recognise glycans attached to
aminopeptidase N
To test if the MMC4 antibody was binding to a glycan on APN, APN was incubated
with either N-glycosidase F or O-glycosidase to remove N-linked or O-linked glycans
respectively.
O-linked glycans were removed from commercial APN as shown by the slight decrease
in molecular weight found after treatment (gel not shown). ELISA based dot blot
analysis (figure 27) shows that this decrease in molecular weight does not cause a
corresponding decrease in MMC4 reactivity. This suggests that the MMC4 monoclonal
antibody is not binding to a O-linked glycan.
N-linked glycan removal was not complete, as shown by the SDS-PAGE gel (figure
28). This was due to the reaction conditions not being optimal. Optimal conditions for
this reaction, however, involved denaturing the APN protein and therefore the MMC4
antibody would not recognise the APN protein at all. Sub-optimal conditions were used
to cause partial cleavage of the N-linked glycans. This caused some APN to be lose N-
linked glycans as shown by lane 2 in figure 28. After immunoprecipitation with MMC4-
coated Dynabeads®, the APN band minus N-linked glycans is still present, suggesting
that the MMC4 Monoclonal antibody is not binding to an N-linked glycan.
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Standard deviation error bars shown
Figure 28: Analysis of ELISA based dot blot results from MMC4 monoclonal antibody
recognition of aminopeptidase N both before and after incubation with O-Glycosidase.
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Figure 29: 6% acrylamide gel of aminopeptidase N plus and minus N-Glycosidase F
(which removes N-linked glycans from the protein) both before and after immuno-
precipitation using magnetic beads bound with MMC4 Monoclonal antibody. The
presence of the deglycosydated APN band after immuno-precipitation shows that the
MMC4 Monoclonal antibody is not binding to N-linked glycans.
1 = Molecular weight makers
2 = Aminopeptidase N plus N Glycosidase F
3 = Aminopeptidase N
4 = Immunoprecipitated (via Dynabeads coated in MMC4 antibody) aminopeptidase N
5 = Immunoprecipitated aminopeptidase N after incubation with N Glycosidase F
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7.3 Discussion
MMC4 reactivity was found in the BAL of both S. aureus instilled and non-instilled rats.
Levels of reactivity were found to increase after S. aureus instillation. These two
findings suggested that the MMC4 antibody could be used as a marker of AETII and
Clara cell injury within the lung in a non-invasive manor. However until the antigen and
its specificity was fully known, it would not be appropriate to say that the increase in
reactivity was due to the damage of these two cell types.
The MMC4 antigen was purified from the lung, kidney, thymus, liver and small intestine
of SD rats via antibody coated Dynabeads®. In all organs the top 'hit' in the SwissProt-
TrEMBL database for the isolated protein was aminopeptidase N (APN). This finding
was confirmed via Tandem MS of the kidney isolated protein. Further biochemical
confirmation showed that the MMC4 monoclonal antibody does bind to APN using
commercially purified APN.
APN had been previously discounted as a possible antigen for the MMC4 monoclonal
antibody as macrophages in initial screenings were thought to be negative. Re-
evaluation of the MMC4 monoclonal antibody binding status to macrophages showed
that, in the normal lung, while most macrophages are negative for MMC4 binding, some
macrophages are positive (approximately 8%). ELISA based dot blot revealed that the
brain and liver appeared negative for MMC4 reactivity (Boylan, thesis), even though
APN is known to be expressed in these organs (Larringa, 2005, Jardinaud, 2004).
Repetition of this ELISA based dot blot using liver homogenate still showed the liver to
be negative for MMC4 reactivity, however, it was possible to immuno-precipitate APN
from the liver using MMC4 monoclonal antibody coated Dynabeads'1". However, to do
so, very high protein levels (101 pg) were required. This amount of protein corresponds
to a volume of organ homogenate far greater than that which can be placed on a dot blot
manifold. As the ELISA based dot blot therefore is not a sensitive test of the presence of
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APN within the organ, the brain could also be positive, but at a level lower than is
measurable via the technique being used.
Each organ had a slight different molecular weight on the acrylamide gel, this could be
due to differences in glycosylation of the protein. Variable glycosylation states are
known to occur, for example in humans there are three known glycosylation states: the
unglycosylated llOkDa, partial glycosylated at 130kDa and the fully functional
glycosylated form at 150kDa (Van De Velden, 1999). N-glycosidase F and O-
glycosidase treatment of the commercial APN showed that the antibody is recognising
the peptide backbone of APN. MMC4 monoclonal antibody has also been shown not to
recognise the active site of amino acid cleavage, or the binding site of L-Ala-pNA, an
artificial substrate for APN.
APN is a membrane bound metallopeptidase. The main known function of APN is to
cleave the N-terminal amino acids off small peptides, rather to aid in peptide
degradation (for example in the intestine (Riemann, 1999)) or to activate proteins. APN
substrates include enkephalins, angiotensins, neurokinins and cytokines (Firla, 2001).
Potential functions of APN in matrix degradation (Saiki, 1993), angiogenesis
(Pasqualini, 2000) and antigen processing (Dong, 2000, Larsen, 1996) have all also been
proposed.
Within the lung APN mRNA production has been shown to be regulated by an
alternative promoter to that in many other organs (Gillis, 1998). This alternative
promoter is the same as that which regulates CD 10, surfactant proteins A, B and C and
Clara cell specific protein (Gillis, 1998).
As aminopeptidase N is the antigen for MMC4 this antibody would not be useful as a
marker of AETII cell and Clara cell damage via BAL analysis, due to this proteins
presence on macrophages. However, the antibody is still useful in studies of lung repair
(via immunohistochemical studies) due to the continuance of APN expression after
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RTII70 expression is lost in the transdifferentiation ofAETII cells to AETI cells (Clegg,
2005).
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8. Characterisation of the MMC6 antigen
8.1. Introduction
AETI cells already have a range of biomarkers in the literature, however, except for
R.TI40, these all also recognise other cell types in the lung as well as the AETI cells.
RTI40 recognises a 40kDa protein of unknown function. Until a function is assigned to
the protein (Tla) this antibody can not be used as a biomarker for drug testing as it is
unclear what pathway within the cell is being affected.
In the process of making novel AETII antibodies (e.g. MMC4, previous chapter), G.
Boylan also produced a marker of AETI cells, MMC6 (isotype IgG2b). Initially it was
assumed that this antibody would recognise the Tla protein that RTI40 also recognises.
However resent work in co-localisation of the RTI40 and MMC6 antibody via
immunohistochemistry by G. Clegg (unpublished) showed that RTI40 and MMC6
monoclonal antibody were not always co-localising on the alveolar membrane. C.
Tyrrell in a study of Streptococcus pneumonia has found that while RTI40 antigenicity
levels in the lung decrease, MMC6 antigenicity levels remain the same (unpublished
communication). These two studies suggest that the MMC6 monoclonal antibody is not
recognising the same antigen as RTI40.
The hypothesis of this study was therefore:
1. MMC6 monoclonal antibody recognises a protein associated with AETI cells
2. The MMC6 monoclonal antibody is useful as a biomarker ofAETI cell injury in
the rat lung.
MMC6 monoclonal antibody was raised via 2 injections of an enriched type II cell
preparation from SD rats into female BALB/c mice. The resulting sera was screened for
reactivity to rat AETII cells on frozen sections of the lung. As already mentioned
MMC6 monoclonal antibody was however found to recognise AETI cells and not AETII
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cells. Hybridomas were then re-cloned three times to ensure a single clone was in the
preparation. MMC6 monoclonal antibody recognising AETI cells is thought to be due to
either contamination of AETI cells in the enriched AETII cell preparation injected into
the BALB/c mice, or due to the AETII cells within the preparation beginning to undergo
differentiation into AETI-like cells, which they do in culture.
8.1.1. Strategy
As very little is known about the MMC6 antigen, except that is found on AETI cells in a
rough screens of antibody recognition, the strategy for identifying the antigen was going
to have to start at first principles. Figure 30 shows an overview of how I intend to
characterise the antigen, first of all finding the organ distribution of the antigen, then
investigation into what the antigen is (i.e., protein, carbohydrate), followed by where on
the cell the antigen is found and finally what exactly the antigen is. Due to the MMC6
antibody being made via the same method as the MMC4 antibody, it is expected that,
like the MMC4 antibody, it will not be possible to purify the MMC6 antigen via western
blotting. Due to this initial screening for antigenicity will be earned out using the
ELISA based dot blot system. At the same time as identifying the MMC6 antigen I also
plan to show that MMC6 reactivity can be found in the BAL fluid and that these levels
increase after S. aureus injury.
8.1.1.1. Disruption of cell membranes
Due to the method used to produce this antibody it is predicted that the antigen will be a
membrane associated protein. As with the MMC4 monoclonal antibody to purify the
antigen I would therefore have to disrupt the cell membranes so that the protein could be
isolated. There is a range of methods to do this. Firstly, 1 could use mechanical
disruption, such as sonication or homogenisation. Homogenisation works by suspending
the tissue of choice in a liquid and then rotating blades cause the tissue to be sheared
into smaller and smaller pieces. Sonication works by using bursts of sound waves to
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Figure 30: Overview of the planned method for identifying the MMC6 antigen
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cause the cell membranes to break up. Both these techniques however cause uneven
breaking on the tissue, as tissue nearest the probes end up being affected more that tissue
further away. These techniques also cause the tissue to heat up which can in turn destroy
antigenicity by denaturing the protein. More recently the preferred technique for
disrupting cell membranes has been to use detergents.
8.1.1.2. Detergent solubilization of cell membranes
Detergents break up lipid-lipid and lipid-protein bonds causing the resulting fragments
to form micelles. Different detergents have different success in disrupting the cell
membrane. For example, Triton X-100 is often used when studying lipid rafts as it does
not break these cholesterol rich regions of the membrane into small pieces, while other
areas of the cell membrane are fragmented (Schuck, 2003). CHAPS is also used in a
similar way, but does partially break up the lipid rafts (Magee, 2003). For studies of the
membrane proteins octyl-(3-o gluoside and Dodecyl-P-o-maltoside are often used as both
are gentle detergents that do not change the protein from its native state (McGregor,
2003). As the location of the MMC6 antigen within the cell membrane was unknown, a
range of detergents were chosen to test to optimise MMC6 antigen recovery.
8.1.1.3. Edman degradation
Edman degradation is a method of finding the amino acid sequence of a protein by
continuously cleaving the N-terminal amino acid from the protein and identifying the
amino acid based on weight. In basic conditions (pH 9) protein and
phenylisothiocyanate in gaseous form react to form a phenylthiocarbamyl derivative at
the N-terminus of the protein. Trifluoroacetic acid then cleaves off the first amino acid
as the anilinothialinone derivative. The anilinothialinone derivative then passes through
the machine aided by addition of N-butyl chloride and converted to a
phenylthiohydantoin. The phenylthiohydantoin is then analysed for the molecular weight
from which the weight of the amino acid can be determined.
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8.2. Results
8.2.1. Screening for MMC6 antigen in multiple organs
Most organs from adult, male SD rats were isolated (ovaries and placenta was harvested
from a female breading SD rat) and homogenised in TBS as described in methods. All
homogenates were then diluted 1:5 and 1:10 in TBS (except the lung (1:1000, 1:5000))
and vacuumed onto a PVDF membrane. An ELISA based dot blot was preformed, and
the X-ray film was analysed as described in methods. I found that all organs (except the
lung) were negative for antigenicity to the MMC6 antibody with this method (figure 31).
This would suggest that the MMC6 monoclonal antibody recognises a molecule that is
specific for the lung.
8.2.2. MMC6 Immuno-histochemistry of the lung
Frozen sections of untreated SD rat lungs were stained with MMC6, MMC4 and RTII70
antibodies (Figure 32) or stained with MMC6, RTI40 and anti-calveolin antibodies
(Figure 33), to test if the MMC6 antigen if found on type I, type II or both alveolar
epithelial cell types. Figure 32 shows co-localisation of the AETII cell associated
antibodies MMC4 and RTII70. However the MMC6 antibody (shown as green) does not
co-localise with these two antibodies, suggesting that the MMC6 antigen is not found on
AETII cells. However, MMC6 staining does co-localise with the RTI40 and anti-
calveolin antibodies (figure 33), suggesting that the MMC6 antibody a marker of AETI
cells. Freshly isolated type II cells do not express MMC6 antigen, and day 5 Type II
cells in culture, which are type I cell like, do express MMC6 (S. McKechnie, personal
communication), further suggesting that MMC6 monoclonal antibody is AETI cell
specific.






































Figure 31: Distribution of the MMC6 antigen in SD rats as found via ELISA based dot
blot.
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Figure 32: Immunohistochemistry of a frozen normal lung section. MMC6 antibody
staining (green) is not co-localising with MMC4 (blue) or RTII70 (red) antibody staining.
This suggests that the MMC6 antibody does not recognise the same cell type as the
MMC4 or RTI70 antibodies.
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Figure 33: Immunohistochemistry of
a normal lung section. MMC6
(Green) is expressed in the same
locations as RTI40 (red) and
Calveolin (blue). This suggests that
the MMC6 antibody is expressed by
AETI cells
Page 137 of 205
8.2.3. MMC6 monoclonal antibody recognises a protein
Lung homogenate was treated with Proteinase K, an enzyme that degrades most known
proteins, overnight at 37°C. The following day samples were tested for remaining
MMC6 antigenicity via ELISA based dot blot. Controls of just Proteinase K, lung
homogenate incubated at 37°C overnight and lung homogenate stored at 4°C were also
tested. Figure 34 shows that little to no antigenicity was lost from the lung homogenate
due to heating overnight, however were Proteinase K was added the antigenicity to
MMC6 was almost obliterated. This strongly suggests that the MMC6 antigen is a
protein.
8.2.4. MMC6 antigen as a membrane protein
From the immunohistochemistry (figures 32 & 33) it appears that the MMC6 antigen is
confined to the membranes of the type I cells. To test this, high gravitational forces were
used to separate membranes from lung homogenate. Figure 35 shows that after spinning
at 500,000g the majority of the MMC6 antigenicity is in the pellet, were all cellular
membranes would be found.
The type of membrane binding was further tested by use of a carbonate wash, which
causes peripheral proteins to be detached from the membrane. After a further 500,000g
centrifugation the MMC6 antigenicity still remains in the membrane pellet (figure 35).
This indicates that the MMC6 antigen is either an integral, or a trans-membrane protein.
8.2.5. Solubilization of lung membranes
As the MMC6 antigen is membrane bound the conventional method to purify the
antigen would be to initially solubilize the membranes with a detergent. To be
considered a successful detergent for our proposes the detergent must a) not cause a
confirmation change to the protein resulting in the MMC6 monoclonal antibody being
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LH 4°C
Figure 34: The MMC6 antigen is a protein. LH= lung homogenate, Pk= Proteinase K.
Addition of Proteinase K to lung homogenate destroys all antigenicity to the MMC6
antibody, suggesting that the antigen is a protein.
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Figure 35: MMC6 monoclonal antibody recognises an integral membrane protein. 1:
untreated lung homogenate 2: supernatant after 500,000g ultracentrifugation, 3: pellet
after 500,000g ultracentrifugation, 4: supernatant after carbonate wash and then
ultracentrifugation, 5: pellet after carbonate wash and then 500,000g ultracentrifugation.
Lane 2 shows tat a small amount of the MMC4 antigen is not membrane bound,
however the majority (60%) is membrane associated. Lanes 4 and 5 shows that the
protein is strongly attached to the membrane, and therefore is most likely to be a trans¬
membrane protein.
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unable to bind to it, b) form micelles of sufficient size to hold the MMC6 antigen, but
not so large that thy are separated out with the membranes after a 500,000g
centrifugation c) the detergent can not denature or interfere with the MMC6 antibody.
To find a detergent that fulfilled these roles a range of non-ionic, anionic, Zwitterionic
and Chaotropic agents were tested both in the absence and presence of Caproic acid (a
hydrogen donator/acceptor to maintain the correct pH) to see if they were useful
detergents for our purposes. Usefulness was assessed using ELISA based dot blots.
Figure 36 gives an overview of the methods used to assess MMC6-detergent
compatibility. Initially all detergent, lung homogenate mixtures were assessed to see if
the detergent would cause lose of antigenicity. Figure 37 shows a typical result for a
detergent that reduced antigenicity and shows a complete list of all detergents that I
tested that caused this response. As expected SDS is in this group, this therefore means
that purification of the MMC6 antigen via Western analysis would not be possible. I
then took lung homogenates with detergents that still showed antigenicity and spun then
at 500,000g to pellet the membranes. I again tested un-spun, supernatant and pellet, as
well as untreated lung homogenate, via ELISA based dot blot to see were the antigen
was found. Figure 38 shows an example of a detergent where the antigenicity for the
MMC6 monoclonal antibody was found in the pellet, suggesting that the detergent was
not solubilizing the membranes completely. Figure 38 also gives a full list of detergents
that I tested that did not cause a loss in antigenicity, but did not solubilize the
membranes sufficiently for MMC6 coupled Dynabead purification.
One mixture of detergents at this stage was fulfilling my specifications, a Urea Lysis
buffer (0.2M DTT, 7M urea, 50mM HEPES (pH7.6), 0.1M NaCl, 0.05% Triton X-100
(v/v), lOmM NaF). Unfortunately, the presence of DTT and the levels of Urea in this
were so high (7M) that it denatured the MMC6 monoclonal antibody, making it
unsuitable for Dynabead analysis (data not shown). Removal of the DTT and lowering
the urea concentration to a safer level unfortunately caused the buffer to lose its ability
to solubilize the MMC6 antigen (figure 39).
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Figure 36: Overview of testing of detergents for ability to solubilize the MMC6 antigen
for Dynabead purification
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Figure 37: Detergents that caused a loss in Antigenicity after 1 hour 4°C
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Figure 38: Detergents where antigenicity remains, but no solubilization
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Figure 39: Affect if decreasing the urea concentration on ability of the urea lysis buffer
to solubilize the MMC6 antigen.
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8.2.6. Mechanical methods of disrupting the cell membranes
As detergents did not appear to be working effectively as a method of disrupting the cell
membranes, I decided to try using mechanical methods, such as sonication and harsher
homogenisation. Sonication did not cause a loss in antigenicity (measured by ELISA
based dot blot), however it also did not solubilize the membranes enough to ensure that
the protein was found in the supernatant after a 500,000g spin (data not shown). I then
tried using a homogeniser at 30,000rpm to brake up the cell membranes (a technique
used in breaking cells for RNA extraction) followed by short centrifugation to remove
any larger tissue fragments. This did not remove antigenicity, however if the
homogenate was treated to a 500,000g spin most antigenicity was still lost (data not
show).
8.2.7 Purification of the putative MMC6 antigen
Despite this it was decided to use the 30,000rpm homogenate with a short spin to see if
we could precipitate any proteins from the homogenate via Dynabead purification
(method the same as for MMC4 lung homogenate). Bound proteins were then run on a
10% acrylamide gel. Figure 40 shows that one protein band was found on the gel (mean
weight 61 kDa, n=5). As before the putative MMC6 antigen was sent for identification
via MALDI-TOF mass spectrometry. Figures 41(a-b) show the probabilities of the top
20 hits for 2 different bands. Please note the low MOWSE scores found both times. The
low MOWSE scores indicate that the database was unable to make a definite hit and was
probably because these were 'hits' on the lower molecular weight fragments, which are
more commonly found in all proteins. This suggests that either something has gone
wrong during the trypsin digestion (unlikely as they were preformed by two different
people on different days), or that the peptides are not in sufficient levels to be delected
via this method, probably due to there being insufficient protein in the initial bands
excised from the acrylamide gel (this is the more likely answer as to was difficult to get
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Figure 40: 8% SDS-PAGE gel stained with gelcode showing putative MMC6 antigen
band is found when Dynabeads® are coated with MMC6 Monoclonal antibody, but not
with an IgG2b control antibody. Putative antigen is approximately 60kDa.
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Figure 41a: SwissProt-TrEMBL MOWSE scores from the MALDI-TOF mass
spectrometry of the putative MMC6 protein after trypsin digestion.
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Figure 41b: SwissProt-TrEMBL MOWSE scores from the MALDI-TOF mass
spectrometry of the putative MMC6 protein after trypsin digestion.
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consistent staining of the gels with Gelcode, and even staining with sliver stain was
poor).
8.2.8 MMC6 as a marker ofAETI cell injury
SD rats were instilled with either S. aureus strain 8325-4 or PBS. 4 hours post
instillation rats were euthanized and the BAL fluid and lungs were removed for protein
analysis. Table 17 shows the average innoculum used, the total protein found in the
BAL fluid and the average number of leukocytes recovered in the BAL fluid. Although
there is no change in the protein levels in the BAL at this early time point, there is a 26
fold increase in the number of leukocytes that are found within the lung, showing that
there is already an inflammation response occurring due to the inoculation of S. aureus
into the lungs. This also suggests that at 24 hours post instillation the neutrophil
response to the S. aureus injury is decreasing as there is only an 8 fold increase in
neutrophils at 24 hours post instillation (see 7.2.1, table 17).
Figure 42 shows that levels of MMC4, MMC6 and RTI40 reactivity found in the BAL
fluid of PBS and S. aureus treated rats. RTI40 has previously been shown to be increased
in the BAL 24 hours post instillation (McElroy, 1999). Here it is shown that a 5 fold
increase in RTI40 levels in the BAL can be detected within 4 hours of injury. However
this increase is not statistically significant. No significant change was found in MMC4
levels, further confirming earlier observations that the initial leukocyte infiltrate into the
lungs is mainly neutrophils (which do not express aminopeptidase N) and not
macrophages (aminopeptidase N positive). MMC6 levels within the BAL were found to
increase 4 fold; however, this again was not a statistically significant result. The
similarity between the fold increases in MMC6and RTI40 detection within the BAL
suggests that the MMC6 antibody could be useful as a marker of damage to the alveolar
epithelium and shows that MMC6 reactivity can be measured within the BAL showing
that the antibody has potential as a non-invasive biomarker.
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Instilled Innoculum size n Protein in the Leukocytes in
(cfu) BAL (mg) BAL
PBS 0 3 1.67 ±0.747 1.73 x 10'
8325-4 1.07 x 10s 3 1.19 ± 0.730 6.46 x 10"
Table 17: Levels of bacteria instilled into rats and levels of protein and leukocytes
recovered in the BAL of rats harvested 4 hours after S. aureus strain 8325-4 was
instilled.
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Figure 42: Relative densitometry units (RDU) of MMC4, RTI40 and MMC6 recovered
from the BAL fluid via ELISA based dot blot from rats harvested 4 hours after either S.
aureus strain 8325-4 or PBS instillation.
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8.3 Discussion
While not managing to identify the MMC6 antigen I have shown that the antigen is an
integral membrane protein expressed exclusively on AETI cells within the lung.
Currently there are no other proteins known to be completely specific for AETI cells.
Although I was unable to solubilized the cell membranes using detergents in a manner
that would enable immuno-precipitation to work, a potential MMC6 associated protein
was isolated via mechanical disruption of the cell membranes. This protein has a
molecular weight of approximately 60kDa. Initially I had reservations about this protein
as it is very similar molecular weight to albumin, however MALDI-TOF mass
spectrometry followed by SwissProt-TrEMBL analysis did not return albumin as a high
'hit'. However as no known protein was returned by this method there is still a
possibility that the isolated protein is albumin contamination.
Attempted solubilization of the cell membranes to isolate the MMC6 antigen has shown
that the antigenicity of the MMC6 monoclonal antibody is conformation dependent (as
shown by the inability of the antibody to recognise the antigen after SDS treatment).
Due to this western blot analysis to find the protein's molecular weight was not possible.
An alternative method to isolate the MMC6 antigen would be to try a gene expression
library. Alternatively, traditional affinity columns, Triton X-114 separation or western
blotting without reducing agents could also be tried if the gene expression library was
not successful.
The pilot study into MMC6 being used as a marker of AETI cell damage via measuring
MMC6 reactivity within the lung showed that MMC6 can be measured within the BAL
fluid, and that differences in the levels ofMMC6 expressed were similar to those found
with RTI40. This suggests that further work into this antigen is advisable as it does have
the potential to be a marker ofAETI cell damage if the antigen can be identified.
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9. Discussion
The US Congress ruling in 1997 giving the FDA authority to grant marketing approval
of devises to aid in the diagnosis, prognosis and selection of participants to drug regimes
has greatly increased the number of potential biomarkers that are being converted from
laboratory based tests to assays being used in the medical arena. However, considering
the wide use of biomarkers within laboratories only a small fraction of these are making
it through to clinical practice. Part of this is due to the criteria set down by the FDA
which mean that the biomarker has to be more rigorously tested before it can be
approved for human use than the testing is on many laboratory markers.
Weir et al (2006) argue that a biomarker should not just correlate to a clinical endpoint,
but rather the effect of a treatment on the surrogate endpoint being measured by the
biomarker should also correlate with the treatments' effect on the final endpoint. This
thesis, instead of looking for biomarkers of a specific disease, has investigated markers
that indicate a change to the alveolar epithelium which is often an early site of change in
lung diseases. As a return to 'normal' levels of AETI and AETII cells after a injury is
linked to the lungs returning to normal function the markers I have investigated would
fulfil Weir et a/s' recommendation of a role of a biomarker.
Potential biomarkers are made by a variety of mechanisms. Some are made deliberately,
based on known biological mechanisms of a disease producing likely candidates (e.g.
CD4 levels in the blood of people infected with HIV). Other markers are however made
by random screening of the changes that take place within an organism after
infection/development of the disease.
Based on the finding and pitfalls found during this thesis I would like to propose a
method of identifying and screening the biological usefulness for potential biological
markers.
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9.1 Framework of biomarker development
Biological marker development can be split into distinct stages: development of a
potential marker, producing a reliable assay system for the marker, biomarker
characterisation, determining the biomarker's target population, compare and contrast
the marker to existing markers and finally validation of the biomarker. Most of these
areas overlap so for ease of explanation I have grouped these areas into:
a) Biomarker development and characterisation,
b) Assay development and compare and contrast to existing biomarkers and
c) Biomarker validation and determining target populations.
9.1,1 Biomarker development and characterisation
Methods for developing biomarker candidates depend greatly on a number of factors:
the nature of the disease, availability of information on the disease, presence of
biomarkers/ potential biomarkers already in existence, the preferred techniques of the
researching group and also the eventual target user group (i.e. biomarkers intended for
laboratory use only, un-linked to human diagnostics, tend to be less well researched than
those intended for human diagnosis).
Figure 43 shows an overview of the method of identifying candidate biomarkers that I
am proposing.
Initially research into the area to discover if there are any known biomarkers for the
disease being investigated is required. In my area of alveolar epithelial injury there were
proposed markers of both AETI and AETII cells (RTI40, HTI56 and aquaporin 5 being
the main candidates for AETI cells and Surfactant proteins and Alkaline phosphatase for
AETII cells), however, all these markers have factors that make them undesirable as a
biomarker. RTI40, recognises the Tla protein (Kato, 2003), which currently has no
known function, making linking changes in its levels of expression/ levels in BAL fluid







































































Figure 43: Overview of proposed method of identifying a candidate for investigation as a
biomarker. Salmon boxes = see further figures/text
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to functional/ physiological changes within the body difficult. The antigen for the HTI56
antibody has still to be identified (Dobbs,1999), meaning it has similar difficulties to the
RTI40 antibody. The functions of aquaporin 5 have been well characterised, however, the
protein is also found in bronchial epithelial cells (Nielson, 1997) so any changes in the
expression of the protein can not be contributed entirely to changes in the levels of AETI
cells. The AETII cell associate proteins mentioned above also have similar difficulties
as the AETI associate proteins. This therefore means that the current markers can not be
considered to be accurate. Due to the known inaccuracies/limitations of existing markers
of the alveolar epithelium investigations into new markers would be appropriate.
The actual numbers of AETI and AETII cells lining the alveoli would be the ideal
feature to examine in lung diseases. However getting samples of the lung from living
patents to investigate is not recommended and therefore direct looking at the lung
surface is not feasible as a method of predicting the likely outcome of lung injury.
Investigations into phenotyping the alveolar epithelium using immunohistochemistry
within our research group produced new two antibodies which bind to the alveolar
epithelium. The MMC4 antibody had already been shown to bind to the apical surface of
AETII cells and Clara cells and the MMC6 antibody was suspected to recognise a
antigen associated with AETI cells. Both these antibodies were therefore considered as
potential biomarkers during this thesis. Once a potential biomarker is identified further
characterisation is required to find which cell types express the biomarker, where the
active protein is located, what the protein is and what the functions of the protein are.
Information from literature searches should be used at this stage to ensure all possible
functions/ locations of the biomarker are investigated as assays are often limited to one
functional characteristic of a protein, and also do not recognise all forms of a protein.
As already discussed, the MMC4 antigen was found to be aminopeptidase N via mass
spectrometry and biochemical analysis. Previous work by Boylan et al (2001) had
already shown the distribution of MMC4 antibody biding throughout the rat. Once the
antigen was known to be aminopeptidase N, a comparison of the distribution of
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aminopeptidase N found in the literature and by Boylan et al experimentally was carried
out. This found that aminopeptidase N was expected to be expressed by macrophages,
which Boylan et al had found to be negative for MMC4 antigen expression via
immunohistochemical analysis of frozen lung sections (Boylan, 2001). Further
investigation into MMC4 reactivity via ELISA based dot blot and
immunohistochemistry found that a small percentage of macrophages were positive for
aminopeptidase N, suggesting that the original screening assay was not rigorous enough.
The MMC6 antigen was found to be expressed by AETI cells exclusively. However, I
was unable to purify the antigen via its affinity to the MMC6 antibody attached to
Affymetrix beads. The possibility of the MMC6 antibody being a biomarker is therefore
still unanswered.
Up and down regulated genes were compared to the change in expression of genes
known to be associated with AETI/AETII cells. Most known AETII cells associated
genes did not change in expression, therefore, this model is not appropriate to investigate
potential AETII cell markers. Some AETI cell associated genes did decrease in
expression significantly. Genes with a similar decrease in expression were therefore
investigated for association with AETI cells. At the same time, down-regulated genes
were screened to check for 'unusual' results, which could cast doubt on this method for
identifying AETI cell associated markers. Gene expression of CD9, a protein known to
be associated with macrophages, was noticed to decrease. This was not expected as
macrophage levels had increased within the lung. Further investigation however showed
that CD9 is also expressed by AETI cells and the decrease in this cell type could have
been the cause of the decrease in CD9 expression. The remaining genes with decreased
expression comparable to known AETI cell associated proteins were investigated to find
potential novel markers. Investigations are still ongoing to see if any of these genes are
useful as markers ofAETI cells.
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9.1.2 Assay development and compare and contrast to existing biomarkers
A biological marker of injury/ disease is only as good as the assay that is used to detect
it. A realisable system of producing an assay is required to a) keep the costs of
producing the assay to a minimum b) to ensure that the assay will produce statistically
reproducible accurate results. Figure 44 shows an overview of my proposed method of
assay development.
If there already and assay for the biomarker available this should be considered first as
this would drastically reduce the cost of developing a new assay. If the biomarker being
examined is a physiological feature, such as in cancers, then imaging techniques would
give the most obvious starting point for assays.
One consideration, which is often missed out in other proposed methods of assay
development (Flammond, 2002), is the comparison between the newly developed assay
and those already on market with regards to how invasive the collecting of samples for
the assay/ the assay itself is. Highly invasive methods of obtaining samples (such as
biopsy) are less popular now. If an alternative less/non-invasive technique could be
developed then this is more likely to gain FDA approval than producing an assay for a
disease that already has a non- invasive method of identification/prognosis.
In the case of the MMC4 and MMC6 antibodies that I was investigating, both had been
designed for immunohistochemical investigations on frozen lung sections. This would
require lung biopsy to obtain samples. ELISA based dot blots had already been used to
measure the levels ofMMC4 reactivity in tissues within our laboratory group. This was
extended to measuring the levels ofMMC4 and MMC6 reactivity within the BAL fluids
recovered from the lungs. I have shown that this technique is successful in recognising
changes in the lung caused by S. aureus instillation into the lungs of rats. ELISA based
dot blot measurements of the MMC4 antigen were however shown to be unreliable (it
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Figure 44: Overview of proposed method of choosing an assay system for a new
biological marker.
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was possible to purify the antigen from the liver which the ELISA based dot blot assay
had shown to be negative for the antigen). If the MMC4 antibody had continued to be
useful as a biomarker after the antigen was identified a different assay system would
have had to be developed as current assay was not accurate enough.
In some cases more than one assay may be already available for a biomarker. In these
cases I recommend that all available assays are used initially. This will enable a
comparison of which assay is the most reliable to be carried out, improving the quality
of the biomarker. If two or more assays are equally accurate then other factors, such as
how invasive sample collection is, cost to produce the assay, ease of performing the
assay should be considered. In my field of lung injury, sample collection is via biopsy
(rarely), BAL fluid collection or by exhaled breath condensation. As biopsy should be
avoided if possible and samples from exhaled breath are not always possible to acquire
(such as from patients with reduced lung capacity), currently I feel that BAL fluid
analysis is the best method for obtaining samples to use for diagnostic and prognostic
analysis.
Once an assay system has been selected conditions (such as type of specimens (fresh,
frozen or fixed), physical conditions (pH, temperature, antibody concentrations,
reagents)) and a scoring system for the assay need to be developed. Most assays
developed do not have just a positive and negative result, but rather are measured on a
scoring system of how much the biomarker is present. A 'cut off point is therefore
required from positive and negative results, with a 'at risk'/'result inconclusive' area in
between. Detailed statistical analysis (such as that described by Weir et al (2006)) is
required to ensure that these 'cut off points are accurately placed.
9.1.3 Biomarker validation and determining target populations
Once a potential biomarker has been identified and an assay system developed, the
biomarker needs to be validated. This includes the following tests:
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(a) Diseased vs. control samples
(b) Controls from different ethnic groups
(c) Diseased from different ethnic groups
(d) Diseased vs. those with similar symptoms
(e) Diseased on treatment vs. no treatment (at different time points after treatment
started)
(f) Diseased on medication for other illnesses
The overall bases of tests (a-c) are to confirm that the biomarker can distinguish between
healthy and disease samples in all populations, (d) Shows the ability of the biomarker to
differentiate between diseases showing the accuracy of the biomarker. Tests together
confirm the biomarkers usefulness as a diagnostic marker. Test (e) shows the possibility
of the biomarker as a prognostic biomarker. Test (f) is useful for validating both
diagnostic and prognostic biomarkers as it shows how reliable the results are when there
are multiple diseases, with multiple treatments. However, picking samples for (f) can be
difficult as not only do the diseases have to be relevant to each other, but enough
patients are required to ensure that statistical tests can be carried out. For example
groups that should be tested for bacterial biomarkers should include people with
suppressed immuno systems (either through drugs or illness). Those who are prone to
infections for other reasons (I.E. in cystic fibrosis patients and asthmatics) should also be
tested.
9.2 Characterisation of S. aureus induced pneumonia in rats
As well as answering the main questions of my thesis, regarding alveolar epithelial
biomarker development, I have also further characterised the S. aureus model on
pneumonia used within our laboratory group.
4 hours post inoculation data had not previously been collected. I have shown that
although there is no significant damage to epithelium at this time point there is a large
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influx of neutrophils to the site of infection. This influx of neutrophils could therefore be
a contributing factor to the injury to the alveolar epithelial surface. At 24 hours post
instillation there are still elevated levels of neutrophils within the lung, but not as high as
at 4 hours, suggesting that production of molecules which are chemotactic with regards
to neutrophils has decreased. By 72 hours there are few neutrophils remaining within the
lungs; however, there are a large number ofmacrophages/monocytes, possibly removing
damaged neutrophils/cells from the lung.
Global gene analysis at 72 hours post instillation suggests that the endothelium could
also be damaged, due the large number of endothelial cell associated genes being down
regulated. Previous biochemical analysis preformed by G. Clegg et al had found no
damage to the endothelium (measured as presence of cfu into the blood and CC10 levels
in the BAL). However the decrease in expression of genes that are endothelial associated
does cast doubt on these previous findings.
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10. Further work
Although I still have questions that I would like to answer with regards to all three ofmy
research areas, these are all surplus to the problem I set out to solve in my thesis. The
characterisation of the cellular and molecular response to injury within the lung still
requires further investigation and I feel that biomarkers have a strong role within this
area, both in the clinical setting and as a research tool. I would therefore like to see
more research into cell associated proteins as a method of identifying candidates for
biomarkers. I would also like more collaboration between researches using proteomic
and genomic platforms as a method of identifying markers that area commonly
increased in lung injury as well as those that are disease specific.
Currently the FDA produces guidelines into how a biomarker should be validated. I
would welcome a structured approach to biomarker development and validation and feel
that a framework, such as the one I have suggested, would make it easier to identify gaps
in knowledge required in drug approval applications. This would be due to
oversights/missing information with regards to the surrogate endpoint being easier to
identify if there are strong guidelines/recommendations detailing exactly what
information is the base line requirement for a characteristic to qualify as a surrogate
endpoint.
However, testing of this framework is required with a larger range of types of
biomarkers and number of biomarkers before it could be widely accepted.
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Appendix i
Computer programs used in the analysis of Affymetrix data.
On the Affymetrix U34 gene chips there werell exact mach probes and 11 one base
mismatch probes for each gene. Gene chips were prepared as described previously (see
6.1.1). Te U34 chips were scanned and the raw data was analysed in MicroArray Suite
by Affymetrix to assign a value to each probe set.
Affymetrix MircoArray Suite
He Affymetrix program first of all reads the outside of the scanned chip where the
positive and negative controls form a checker board effect. This allows the software to
align a grid over the chip so that it can calculate which 'spots' are assigned to which
gene. The right hand side of figure 10 shows part of these control probes that were used
to align the grid. Readings from the centre of each spot (8x8 pixels) are then used to give
a positive reading of each spot. The background reading for the chip (calculated as the
average of the lowest 2% of the spot readings on the whole chip) is subtracted from all
'positive' readings This would allow for any variation between chips with regards to the
hybridization of the phycoerithin stain, or variation in washing off the excess stain. The
program also measures the variation between pixel intensity for each spot, reducing the
effect of any minor changes in hybridization.
After 'normalization' across the chip the 11 exact match and 11 one base mismatch
readings were collated to give a single reading for the intensity of the gene. As well as
this reading the algorithm also gives a probability of this intensity being a true reading
(based on the variation in the 22 spot readings).
The data from the chips was then loaded into GeneSpring.
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GeneSpring
GeneSpring is a software package widely used in conjunction with gene expression
profiling. This is due to the programs ability to filter large quantities of data via a wide
range of parameters which the research can set. The program also allows the researcher
to perform a wide range of statistical analysis on the data using one /two way ANOVAs,
Turkey and Student-Newman and Keults post hoc tests. The software also allows for
analysis of false discovery rates and multiple testing corrections. Despite all the
statistical analysis that can preformed using GeneSpring most papers citing GeneSpring
have used the pictorial representations of the data that can be obtained.
This package allows the researcher to view the genes intensity values as a colour ranging
from blue (lowest) to red (highest). Pictorial representation, such as figure 11, of the
genes can show multiple sets of information at once. For example, figure 11 shows the
intensity of the gene as well as the fold change in the gene. Other pictorial
representation that the software can perform include looking at all known gene that
encode for a specific pathway and showing if the increase/ decrease in expression, again
using the colour to show change. This is also useful if multiple repeats of the same
experiment were analysed as it shows any variation between repeats easily.
Using GeneSpring it was possible to isolate a list of genes that have either increase or
decreased greater than 2 fold after treatment. However I found that when I compared
this to the list I had in excel of genes that had increased/decrease 2 fold these lists were
not identical. As it is possible to see the raw numeric data in excel and not in
GeneSpring, this finding raised questions as to how GeneSpring was processing the data.
The majority of GeneSpring's data analysis works on the basis of fold change, which
has also been used in this thesis. This carries the assumption that a change in expression
of 10 to 100 would have a similar biological impact as a change from 500 to 5000. Fold
changes however do not work accurately when looking for genes that are either initial
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turned off and then turned on by the treatment, or visa versa; or does fold change work
well on genes that either start or end with very low expression. To overcome these
problems in analysis the data tall genes with an mRNA reading of less than 500 units
absorbance were discounted in my analysis. This does however mean that I may have
missed out any genes that were switched on or off.









Receptorof vascularintestin l polypeptide







































Calcitoninrecept r¬ likereceptor (CRLR)
















































KininaseII(also called angiotensin converting enzyme(ACE))
Bloodpressure,water andsaltmet bolism
Vascular endothelialofth lung,intestitinal andre altubul r epithelialcel s neuroepithelial cells,monocytes, macrophages,T- lymphoctes




















































Vanderliet (2000) Fattman (2003)Zelko (2002)
























Peptidylglycine alpha-amidating monooxygenase (PAM)
Activationofpep des (usuallyhormones)vi amidation
























Tumoursuppressor, regulatesmitogenesis, inflammation responsedevelo ment anddifferentiation
Mostcelltypes


























































































































3.07 2.88 2.68 2.46
8xl0"5 0.0027 0.0005 3x10"5
0.26 0.58 0.40 0.53




























Verkman(1995) Wintour(1997) Fehrenbach (2001)
Developmentally- regulatedcardiac factor(DRCF-5)
UNKNOWN






Developmentally- regulated intestinalprotein (OCI-5)
Inducesapoptosis










































































































































































Fehrenbach (1998),Shirasawa (2004)Katsuoka (1997)Ding (2005)Bierhaus (2005)
Amyloidogenic glycoprotein (rAG)














Vesicle associated membrane protein(VAMP- 2)







































































Facilitatescell-matrix interactions,issue remodelling,cel movement, proliferation


































































Page 198 of 205
MRX Dynatech Medical Products NUNC c/o Fisher Scientific UK Ltd
West Sussex Bishop Meadow Road
Loughborough
LEI 1 5RG
OmniViz Pierce Biotechnology Inc





Delta House Qiagen House
Chilworth Science Park Fleming Way
Southampton Crawley
S016 7NS W. Sussex
RH10 9NQ
Roche Diagnostics Ltd Rockland Immunochemicals Inc




Schleicher & Scheuell Serotech
c/o Whatman International Ltd 22 Bankside
Springfield Mill Station Approach
Maidstone Kidlington
Kent Oxford
ME14 2LE OX5 1JE
Sigma Aldrich Company Stratech Scientific Ltd
Econ Avenue Unit 4 Northfirld Business Park




Page 199 of 205
Appendix vi
European Respiratory Society Conference 2004 (Glasgow) Poster and oral
presentation. Eur Respir J; 24: suppl. 48, 719s.
The type II and Clara cell specific monoclonal antibody (MMC4) recognises
aminopeptidase N
Linda Franklin1, Andrew D Cronshaw2, David J Harrison3, and Mary C McElroy1.
1 MRC Center for Inflammation Research, University of Edinburgh, Edinburgh. 2
Edinburgh Protein Interaction Centre, University of Edinburgh, Edinburgh and 3
Division of Pathology, University ofEdinburgh, Edinburgh.
Abstract:
We have previously described a new monoclonal antibody (MAb), MMC4, which
specifically recognises an integral membrane protein localised on the apical surface
of rat alveolar epithelial type II and clara cells in the lung. It has also been shown
that expression of MMC4 antigen may be associated with type II cells in transition to
type I cells (G. Clegg et al., Thorax 2003; 58 (Supp3): 18). The objective of this
study was to determine the identity of the MMC4 protein.
The MMC4 antigen was immunoprecipitated from octaethyleneglycol mono-«-
dodecly ether (C^Eg) soluble fractions of lung and kidney homogenates using
magnetic beads bound with the MMC4 MAb. One non-IgG associated protein was
obtained, which was at a slightly different molecular weight in each tissue (Table
l)(putative MMC4 antigen). The putative antigen from each organ was trypsin
digested and the fragments sequenced by MALDI-TOF mass spectrometry (MS) and
Tandem MS. In all organs the top 'hit' was for aminopeptidase N (APN) (MOWSE
scores in table 1). The MMC4 MAb also recognises a commercial purified rat APN
protein. Our data suggests that the lung may have specific post-translational
modifications to APN and that APN may be specifically involved in the transition
from type II to type I alveolar epithelial cells.
Organ Lung Kidney Liver Thymus
Molecular weight (kDa) 123 126 113 108
MOWSE score for APN 1.7el6 5el9 3.6el7 4.2el6
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Figure1:MMC4AbstainingofTypIIalveolar epithelialce l(red)surroundedbytyIllsg n) (picturefromBoylanetal,2000) Aim:Topurifyandide ttheMMC4antigen. Methods:
•Lung,kid eyintestine,thymusa dliverhomog natew r solubilisedwithC12E8(1mgprotein:5deterg nt) •C12E8solublehomogenatesw rincubatedi hPaIgG Dynabeads,whichh dbeenpre-coatediththMMC4Ab •Immuno-precipitatedprot insw reremovedfr mthbeadsand runonSDS-PAGEgels •Proteinbandswerecutfthg ldnalyzedviarypsi digestionandMALDI-TOFmassspectrometry •Theprot inbandfromthkid eywaslsoanalyz dviaa dem massspectrometryaftertry sindigestio •MMC4Abactivitywastestedgain tpurif edcomm rcial affinitypurifiedAPM(C lbiochem)invitro) •AbilityofMMC4Abtinhib tPNactivitwastestedus ngn ELISAwithL-Ala-pNAasthesubstrate •Proteinassaysw recarriedutu gmodifiL wrypr ocol
Figure2:RelativlevelsofMMC4indifferenttiss .D tahown asrelativedensitom tryunits(RDU)=4)permgro einith organ(n>7). I ConfirmedMMC4antigenisthkidn y,lu gdoth rrgans Figure3:Immuno-precipitationftheputativeMMC4an igfr m C.,Ersolubli 116 97- 80~1̂homogenate 1si I I2 -̂IgGband(150kDa) l^126kDaun nownprotei
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European Respiratory Society Conference 2004 (Glasgow) Poster presentation
Eur RespirJ; 24: suppl. 48,106s.
Gene expression analysis of lungs following Staphylococcus aureus induced
acute lung injury
Linda Franklin1, Paul Dickinson2, David Harrison3 and Mary C McElroy1. MRC
2 •
Centre for Inflammation Research, University of Edinburgh, Edinburgh; Scottish
Centre for Genomic Technology and Informatics, University of Edinburgh,
Edinburgh; 3 Division of Pathology, University of Edinburgh, Edinburgh.
Abstract:
Staphylococcus aureus is an important cause of community and hospital acquired
pneumonia. We have used a previously established rat model of S. aureus pneumonia
(McElroy, M.C. et. al. Infect. Immunol. 2002;70:3865-3873) to study the changes to
the host's lungs during injury and repair. Previous work has shown that 72 hours post
S. aureus inoculation RTI40, an alveolar epithelial type I cell selective protein is
decreased 10 fold by biochemical analysis and this decrease is associated with a
decrease in the number of type I cells (unpublished data). The objective of this study
was to determine whether we could identify genes specific to type I cells by
investigating genes which are down-regulated after S. aureus injury. Injured regions
of the lung were isolated and the total RNA was extracted. The RNA was amplified
and analysed using an Affymetrix system. We found 99 genes were significantly up-
regulated 2 fold or greater and 136 genes were significantly decreased 2 fold or
greater. Within the decreased genes there were genes known to be associated with
alveolar epithelial type I cells e.g. caveolin I (7 fold decrease (P=0.017, n=3)) and
Aquaporin 5 (2 fold decrease (P=0.01, n=3)). There are 92 other genes that were
significantly decreased between 2 and 7 fold. We are currently investigating these
genes to see if they are expressed by type I alveolar epithelial cells.
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Introduction: Staphylococcusaureusisnm o tantcauseofcomm nitynd hospitalacquiredpneumonia.Wevus dr v ously establishedr tmod lo*S.aureuspneumonia(McElroyt al.,2002)tostudyhechangesh stlungsduringinj r andrepair.Previousworkh ssh wnthat72oursp tS. aureusinoc lationRTI^,nlveolarepith ialtyIselec ve protein,isdecreased20foldbyioch micalanaly isnthi decreaseisa sociatedwithde rnthnumberofypI cells(unpublisheddata). Figure1:TypIcellsstainingwith RTI^MAb(green)incontrolA,B and72hoursp stS.ureu inoculation(C,D).Theproportf alveolarwallstainedthRTI^i decreased,suggestingareduction inthenumberoftypIcellsaft r injury(G.Cleggetal,2004) Figure2:TypIcellmarkersin controla dS.ureustreated lungs.RTI^andaquaporin5re bothd wnregulated10foldand 3foldrespectively(G.Cleggal, 2004) Aim: Toidentifyge esspecifictoypIc llbyinvestigating whicharedownregulatedfterS.aur usinj y Methods: •Ratswereinoculatedi h»10®colonyformi gunitfS.aur us strain8325-4 •72hourspostinoculationlungwe eharvest d,lavagednd perfusedwithsterilePBSandfixiRNAIa er(Amb on) •RNAwasextr ctedfromtheinju dareaflung(Q i en) •CollectedRNAwasamp'ifindrunU34atAffy etrixchip •Collecteddatawasiniti llyprocesseGen Spring •Shortenedlistfgen swasma uallysorte
Figure3:Changinlevelsof expressionofallgenesth U34chip. Thickgreenlin=ochange Thingreenlin s=2fold changeineitherdirection
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Figure6:CD9stainingoftypIcellswithin thelung(A),comparedRTI^ftypI cells(B)andtypeIIllstainingMMC4C). Dshowsmergedimaofallthre antibodies,transmittedimagshownE
MAbagainstCD9hasboundtypeIcelltnoI cellswithinthelung. Thereforeouanalysishide ti iedn wlve lartypI cellsel ctiveprotein Conclusion: Wehavestablishednov lmethodfori dingwtypIc ll genesa dprotein References: G.Cleggetal,2004.submit ed K.Dahlinet.,AmJR spirCellMoBi2004,31(3):09-16 McElroyetal.,Infect.mmunol gy2002,7 (7):3865-3873
Scottish Thoracic Society Winter Meeting 2004 (oral presentation)
The type II and Clara cell specific monoclonal antibody (MMC4) recognises
aminopeptidase N
Linda Franklin1, Andrew D Cronshaw2, David J Harrison3, and Mary C McElroy1.
1 MRC Center for Inflammation Research, University of Edinburgh, Edinburgh. 2
Edinburgh Protein Interaction Centre, University of Edinburgh, Edinburgh and
Division ofPathology, University ofEdinburgh, Edinburgh.
Abstract:
We have previously described a new monoclonal antibody (MAb), MMC4, which
specifically recognises an integral membrane protein localised on the apical surface
of rat alveolar epithelial type II and clara cells in the lung. It has also been shown
that expression ofMMC4 antigen may be associated with type II cells in transition to
type I cells (G. Clegg et al., Thorax 2003; 58 (Supp3): 18). The objective of this
study was to determine the identity of the MMC4 protein.
The MMC4 antigen was immunoprecipitated from octaethyleneglycol mono-n-
dodecly ether (C^Es) soluble fractions of lung and kidney homogenates using
magnetic beads bound with the MMC4 MAb. One non-IgG associated protein was
obtained, which was at a slightly different molecular weight in each tissue (Table
l)(putative MMC4 antigen). The putative antigen from each organ was trypsin
digested and the fragments sequenced by MALDI-TOF mass spectrometry (MS) and
Tandem MS. In all organs the top 'hit' was for aminopeptidase N (APN) (MOWSE
scores in table 1). The MMC4 MAb also recognises a commercial purified rat APN
protein. Our data suggests that the lung may have specific post-translational
modifications to APN and that APN may be specifically involved in the transition
from type II to type I alveolar epithelial cells.
Organ Lung Kidney Liver Thymus
Molecular weight (kDa) 123 126 113 108
MOWSE score for APN 1.7el6 5el9 3.6el7 4.2el6
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